0001553350-21-000868.txt : 20210930 0001553350-21-000868.hdr.sgml : 20210930 20210930155459 ACCESSION NUMBER: 0001553350-21-000868 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 43 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210930 DATE AS OF CHANGE: 20210930 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MediXall Group, Inc. CENTRAL INDEX KEY: 0001601280 STANDARD INDUSTRIAL CLASSIFICATION: RAILROADS, LINE-HAUL OPERATING [4011] IRS NUMBER: 330864127 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-194337 FILM NUMBER: 211295056 BUSINESS ADDRESS: STREET 1: 2929 EAST COMMERCIAL BLVD STREET 2: PH-D CITY: FT LAUDERDALE STATE: FL ZIP: 33308 BUSINESS PHONE: 954-440-4678 MAIL ADDRESS: STREET 1: 2929 EAST COMMERCIAL BLVD STREET 2: PH-D CITY: FT LAUDERDALE STATE: FL ZIP: 33308 FORMER COMPANY: FORMER CONFORMED NAME: CONTINENTAL RAIL CORP DATE OF NAME CHANGE: 20140227 10-Q 1 mdxl_10q-063021.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2021

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________________to__________________________

Commission File Number: 333-194337

MediXall Group, Inc.

(Exact name of registrant as specified in its charter)

Nevada	33-0864127
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)

2929 East Commercial Blvd., PH-D, Ft. Lauderdale, Florida	33308
(Address of principal executive offices)	(Zip Code)

954-440-4678

(Registrant’s telephone number, including area code)

Not applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ¨

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ¨

As of September 30, 2021, the issuer had 106,148,845 shares of its common stock issued and outstanding.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

INDEX

		Page No.
PART I	FINANCIAL INFORMATION

ITEM 1.	FINANCIAL STATEMENTS:	1
	Condensed Consolidated Balance Sheets at June 30, 2021 (unaudited) and December 31, 2020	1
	Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2021 and 2020 (unaudited)	2
	Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and six months ended June 30, 2021 and 2020 (unaudited)	3
	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2021 and 2020 (unaudited)	4
	Notes to Condensed Consolidated Financial Statements (unaudited)	5
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	12
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	16
ITEM 4.	CONTROLS AND PROCEDURES	17

PART II	OTHER INFORMATION

ITEM 1.	LEGAL PROCEEDINGS	18
ITEM 1A.	RISK FACTORS	18
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	19
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	19
ITEM 4.	MINE SAFETY DISCLOSURES	19
ITEM 5.	OTHER INFORMATION	19
ITEM 6.	EXHIBITS	19
SIGNATURES		20

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

MEDIXALL GROUP, INC. AND SUBSIDIARIES

CONDENDSED CONSOLIDATED BALANCE SHEETS


	June 30,			December 31,
	2021			2020
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash	$	125,354		$	645,762
Prepaid expenses - related party		465,000			480,000
Other assets		—			8,000
Total current assets		590,354			1,133,762

Furniture and equipment, net		23,696			26,536

Right-of-use-operating lease asset		7,003			43,757

Website and development costs		452,244			439,404

Total assets	$	1,073,297		$	1,643,459

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	224,436		$	571,405
Accounts payable and accrued expenses - related party		477,231			477,231
Operating lease liability		8,493			47,200
Note payable		—			25,373

Total current liabilities		710,160			1,121,209

Note payable, net of current portion		—			140,346

Total liabilities		710,160			1,261,555

STOCKHOLDERS' EQUITY:
Convertible Preferred Series A stock, $0.001 par value, 1,000,000 authorized; 264,894 issued and outstanding		265			265
Convertible Preferred Series B stock, $0.001 par value, 4,000,000 authorized; 2,984,360 and 1,639,360 issued and outstanding		2,984			1,639
Common Stock, $0.001 par value 750,000,000 shares authorized; 105,389,180 and 98,898,130 shares issued and outstanding		105,389			98,898
Additional paid-in capital		22,827,832			19,862,918
Accumulated deficit		(22,573,333	)		(19,581,816	)

Total stockholders' equity		363,137			381,904

Total liabilities and stockholders' equity	$	1,073,297		$	1,643,459

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)


	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2021			2020			2021			2020

Revenue	$	166,642		$	—		$	169,913		$	—

Operating Expenses
Professional fees		342,080			257,177			681,660			904,441
Professional fees - related party		247,000			103,500			411,038			141,000
Management fees - related party		240,000			120,000			360,000			240,000
Personnel related expenses		682,361			608,337			1,283,911			1,569,827
Other selling, general and administrative		314,417			56,996			424,821			141,827
Total Operating Expenses		1,825,858			1,146,010			3,161,430			2,997,095
Loss before income taxes		(1,659,216	)		(1,146,010	)		(2,991,517	)		(2,997,095	)
Income taxes		—			—			—			—
Net loss		(1,659,216	)		(1,146,010	)		(2,991,517	)		(2,997,095	)

Less preferred stock dividends		59,687			—			106,656			—

Net loss to common shareholders	$	(1,718,903	)	$	(1,146,010	)	$	(3,098,173	)	$	(2,997,095	)



Net loss per common share - basic and diluted	$	(0.02	)	$	(0.01	)	$	(0.03	)	$	(0.03	)

Weighted average number of common shares outstanding during the periods - basic and diluted		102,075,557			87,751,941			101,177,844			86,211,828

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY


	Series A Voting				Series B Voting
	Preferred Stock				Preferred Stock				Common Stock				Additional					Total
	$0.001 Par Value				$0.001 Par Value				$0.001 Par Value				Paid-in		Accumulated			Stockholders'
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance, December 31 2019		264,894	$	265		—	$	—		80,952,554	$	80,953	$	13,966,326	$	(13,649,784	)	$	397,760

Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs (unaudited)		—		—		—		—		1,907,000		1,907		499,843		—			501,750
Common stock issued for services (unaudited)		—		—		—		—		3,964,376		3,964		1,039,101		—			1,043,065
Net loss (unaudited)		—		—		—		—		—		—		—		(1,851,085	)		(1,851,085	)
Balance, March 31 2020 (unaudited)		264,894	$	265		—	$	—		86,823,930	$	86,824	$	15,505,270	$	(15,500,869	)	$	91,490

Proceeds received pursuant to Private Placement Memorandum, net of $3,000 offering costs (unaudited)		—		—						2,350,000		2,350		594,650		—			597,000
Proceeds received from sale of Preferred Stock (unaudited)		—		—		500,000		500						499,500					500,000
Common stock issued for services (unaudited)		—		—		—		—		1,880,000		1,880		468,120		—			470,000
Net loss (unaudited)		—		—		—		—		—		—		—		(1,146,010	)		(1,146,010	)
Balance, June 30 2020 (unaudited)		264,894	$	265		500,000	$	500		91,053,930	$	91,054	$	17,067,540	$	(16,646,879	)	$	512,480

Balance, December 31 2020		264,894	$	265		1,639,360	$	1,639		98,898,130	$	98,898	$	19,862,918	$	(19,581,816	)	$	381,904

Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs (unaudited)		—		—						2,487,550		2,488		619,387		—			621,875
Proceeds received from sale of Preferred Stock (unaudited)		—		—		1,345,000		1,345						1,343,655		—			1,345,000
Net loss (unaudited)		—		—		—		—		—		—		—		(1,332,301	)		(1,332,301	)
Balance, March 31 2021 (unaudited)		264,894	$	265		2,984,360	$	2,984		101,385,680	$	101,386	$	21,825,960	$	(20,914,117	)	$	1,016,478

Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs (unaudited)		—		—		—		—		1,290,000		1,289		326,211		—			327,500
Common stock issued for services (unaudited)		—		—		—		—		2,713,500		2,714		675,661		—			678,375
Net loss (unaudited)		—		—		—		—		—		—		—		(1,659,216	)		(1,659,216	)
Balance, June 30 2021 (unaudited)		264,894	$	265		2,984,360	$	2,984		105,389,180	$	105,389	$	22,827,832	$	(22,573,333	)	$	363,137

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)


	Six Months Ended June 30,
	2021			2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(2,991,517	)	$	(2,997,095	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		2,840			2,000
Common stock issued as compensation for services		678,375			1,513,065
Gain from forgiveness of note payable		(165,719	)		—
Changes in operating assets and liabilities:
Prepaid expenses- related party		15,000			(45,430	)
Other assets		8,000			—
Accounts payable and accrued expenses		(346,969	)		157,720
Accounts payable and accrued expenses - related party		—			(241,870	)
Amortization of right-of-use operating lease asset		36,754			34,302
Operating lease liability		(38,707	)		(33,926	)
Net cash used in operating activities		(2,801,943	)		(1,611,234	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of furniture and equipment		—			(12,429	)
Website development costs		(12,840	)		(14,600	)
Net cash used in investing activities		(12,840	)		(27,029	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the sale of common stock, net of offering costs		949,375			1,098,750
Proceeds from the sale of preferred stock		1,345,000			500,000
Proceeds from note payable		—			165,720
Net cash provided by financing activities		2,294,375			1,764,470

Net (decrease) increase in cash		(520,408	)		126,207
Cash at beginning of period		645,762			446,219

Cash at end of period	$	125,354		$	572,426

Supplemental disclosures of non-cash information
Decrease in note payable resulting from gain on forgiveness of note payable	$	(165,719	)	$	—

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 1 - Organization and Nature of Operation

MediXall Group, Inc. (the "Company “or “MediXall”) was incorporated on December 21, 1998 under the laws of the State of Nevada under the name of IP Gate, Inc. The Company had various name changes since, to reflect changes in the Company’s operating strategies.

MediXall is a technology and innovation-driven organization that has developed a new generation healthcare marketplace platform to address the growing needs of self-pay and high deductible consumers for greater transparency and price competition in their healthcare costs. The cloud-based MediXall.com platform connects patients with healthcare providers and wellness services. The Company’s targeted marketplace is Florida, with plans for a nationwide roll-out. Thus far, MediXall has launched the MediXall platform marketplace throughout Florida beginning in 2019 in a controlled launch and launched Health Karma throughout the U.S. in a beta release beginning in August 2020 and nationwide public launch in November 2020. The Company generated minimal revenue in 2021 and no revenue in 2020 as its online healthcare platform is still in the application and development stage. The revenue recognized in 2021 was driven almost entirely from the Paycheck Protection Program loan forgiveness. Further discussion on our operations, mission, and initiatives can be found in the Management’s Discussion and Analysis section of this report.

The Company has the following wholly-owned subsidiaries: (1) IHL of Florida, Inc., which is dormant, (2) Medixall Financial Group, which is dormant, (3) Medixaid, Inc., and (4) MediXall.com, Inc., which were established to carry out the development and operation of our healthcare marketplace platform, and (5) Health Karma, Inc. which was established in 2020 to increase functionality of the MediXall platform.

Note 2 – Going Concern

The Company has an accumulated deficit of $22,573,333 at June 30, 2021, and does not have sufficient operating cash flows. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplates continuation of the Company as a going concern, which is dependent upon the Company’s ability to establish itself as a profitable business.

Since the Company has generated minimal revenues from its planned operations, its ability to continue as a going concern is wholly dependent upon its ability to obtain additional financing. Since inception, the Company has funded operations through short-term borrowings, related party loans, and the proceeds from equity sales in order to meet its strategic objectives. The Company's future operations are dependent upon its ability to generate revenues along with additional external funding as needed. However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of its business plan. Subsequent to June 30, 2021, the Company has issued 1,499,040 common shares and 665,000 preferred shares for total proceeds of $404,666 and $665,000, respectively.

In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. These unaudited condensed consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying unaudited condensed consolidated financial statements. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 3 - Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information, and the SEC rules for interim financial reporting. Certain information and footnote disclosures normally included in the condensed consolidated financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations. However, in the opinion of management, the accompanying interim condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the Company’s condensed consolidated financial position as of June 30, 2021 and the condensed consolidated results of operations and cash flows for the periods presented. The condensed consolidated results of operations for interim periods are not necessarily indicative of the results of operations to be expected for any subsequent interim period or for the fiscal year ending December 31, 2021. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on June 17, 2021.

Principles of Consolidation

These unaudited condensed consolidated financial statements presented are those of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated.

Use of Estimates

The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates.

A material estimate that is particularly susceptible to significant change in the near-term relate to the determination of the impairment of website and development cost. The Company uses various assumptions and actuarial data it believes to be reasonable under the circumstances to make this estimate. Although considerable variability is likely to be inherent in this estimate, management believes that the amount provided is reasonable. This estimate is continually reviewed and adjusted if necessary. Such adjustments are reflected in current operations.

Subsequent Events

Management has evaluated events occurring subsequent to the unaudited condensed consolidated balance sheet date, through September 30, 2021, which is the date the unaudited condensed consolidated financial statements were issued, determining all subsequent events have been disclosed.

Risks and Uncertainties

The Company's operations are subject to significant risks and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure. Additionally, the Company faces significant risk and uncertainty related to the coronavirus global pandemic (“COVID-19”) pandemic.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Income Taxes

The Company accounts for income taxes using the liability method prescribed by the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification 740, "Income Taxes". Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the year that includes the enactment date.

Pursuant to accounting standards related to the accounting for uncertainty in income taxes, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more- likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than -not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de- recognized in the first subsequent financial reporting period in which the threshold is no longer met. The accounting standard also provides guidance on de- recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.

The Company assessed its earnings history, trends, and estimates of future earnings, and determined that the deferred tax asset could not be realized as of June 30, 2021. Accordingly, a valuation allowance was recorded against the net deferred tax asset.

Revenue Recognition

The Company had minimal revenues in 2021 and no revenue in 2020. The Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation.

Share-Based Payment Arrangements

The Company applies the fair value method in accounting for its stock-based compensation. This standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company values the stock-based compensation at the market price for the Company's stock as of the date of issuance.

Loss Per Share

The computation of basic loss per share (“LPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted LPS is based on the number of basic weighted-average shares outstanding. The computation of diluted LPS does not assume conversion, exercise or contingent issuance of securities that would have an antidilutive effect on LPS. Therefore, when calculating LPS, there is no inclusion of dilutive securities as their inclusion in the LPS calculation is antidilutive.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Following is the computation of basic and diluted loss per share for the three and month periods ended June 30, 2021 and 2020:



	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2021			2020			2021			2020
Basic and Diluted LPS Computation
Numerator:
Loss available to common stockholders	$	(1,718,903	)	$	(1,146,010	)	$	(3,098,173	)	$	(2,997,095	)

Denominator:
Weighted average number of common shares outstanding		102,075,557			87,751,941			101,177,844			86,211,828

Basic and diluted LPS	$	(0.02	)	$	(0.01	)	$	(0.03	)	$	(0.03	)

Potentially dilutive securities not included in the calculation of diluted LPS attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):



Series A Preferred stock (convertible)	24,900,000	24,900,000	24,900,000	24,900,000
Series B Preferred stock (convertible)	11,937,440	—	11,937,440	—

Recoverability of Long-Lived Assets

The Company assesses the recoverability of long-lived assets annually or whenever events or changes in circumstances indicate that expected future undiscounted cash flows might not be sufficient to support the carrying amount of an asset. The Company deems an asset to be impaired if a forecast of undiscounted future operating cash flows is less than the carrying amount. If an asset is determined to be impaired, the loss is measured as the amount by which the carrying value of the asset exceeds its fair value. There was no impairment of long-lived assets pertaining to the three and six month periods ended June 30, 2021 and 2020. However, there can be no assurances that future impairment tests will not result in a charge to operations.

Website and Development Costs

Internal and external costs incurred to develop, the internal-use computer software during the application and development stage shall be capitalized subsequent to the preliminary project stage and when it is probable that the project will be completed. As of June 30, 2021, the Company has met the capitalization requirements and has incurred $452,244 in costs related to the development of the MediXall platform.

Allowance for Uncollectible Accounts Receivable

An allowance for uncollectible accounts receivable is recorded when management believes the uncollectability of the accounts receivable is confirmed. Subsequent recoveries, if any, are credited to the allowance. The allowance is determined based on management’s review of the debtor’s ability to repay and repayment history, aging history, and estimated value of collateral, if any.

Note 4 – Preferred Stock

The Series A preferred shares are convertible into 24,900,000 common shares. The preferred shares do not pay dividends. The number of votes for the preferred shares shall be the same as the amount of shares of common shares that would be issued upon conversion.

On June 24, 2020, the Company filed with the Secretary of State of the State of Nevada (the “Secretary of State”) a certificate of designation (the “Certificate of Designation”) of Series B Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”). The Certificate of Designation was effective upon filing with the Secretary of State and designated a new series of preferred stock of the Company as Series B Convertible Preferred Stock with 4,000,000 shares authorized for issuance.

Upon the occurrence of the events as set forth in paragraph (a) or (b) below, each share of Series B Preferred Stock shall be converted into four (the “Conversion Ratio”) fully paid and non-assessable shares of common stock or any shares of capital stock or other securities of the Company into which such common stock shall hereafter be changed or reclassified (the “Conversion Shares”) as set forth in the Certificate of Designation.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(a) Automatic Conversion

Immediately upon the listing of the common stock for trading on the New York Stock Exchange or the Nasdaq Stock Market, all of the issued and outstanding shares of Series B Preferred Stock shall automatically be converted into Conversion Shares without any further action of any holder of Series B Preferred Stock (each, a “Series B Holder” and collectively, “Series B Holders”).

(b) Optional Conversion

A Series B Holder shall have the right at any time during the period beginning on the date which is six months following the date that the Series B Preferred Stock is initially issued and prior to any automatic conversion as provided in the Certificate of Designation, to convert all or any part of the outstanding Series B Preferred Stock held by such Series B Holder into Conversion Shares at the Conversion Ratio as provided in the Certificate of Designation, subject to limitations set forth in the Certificate of Designation.

Dividends

Series B Holders will be entitled to receive a quarterly dividend, until the conversion of the Series B Preferred Stock, at the rate of 8% per annum (the “Series B Dividend”). The Series B Dividend will be cumulative, shall accrue quarterly, and be paid via the issuance of a number of shares of common stock of the Company equal to (1) the dollar amount of the Series B Dividend being paid, divided by (2) $0.25 (the “Stock Dividend”). The Stock Dividend shall be paid via the issuance to the applicable Series B Holder of the applicable shares of common stock via book entry in the books and records of the Company. At June 30, 2021, cumulative unpaid dividends on the Series B Preferred Stock amounted to $148,778. No common stock has been issued as of June 30, 2021 in satisfaction of the preferred stock dividend.

Voting Rights

Each share of Series B Preferred Stock shall have a number of votes on any matter submitted to the holders of the Company’s common stock, or any class thereof, for a vote, equal to the number of Conversion Shares into which the Series B Preferred Stock is then convertible, and shall vote together with the common stock, or any class thereof, as applicable, as one class on such matter for as long as the share of Series B Preferred Stock is issued and outstanding.

Note 5 – Related Party Transactions

Pursuant to an agreement dated June 2013 and amended in June 2020, TBG Holdings Corp. (“TBG”), was engaged to provide business advisory services, manage and direct our public relations, provide recruiting services, develop and maintain material for market makers and investment bankers, provide general administrative services, and respond to incoming investor relations calls. TBG is owned in part by Neil Swartz, the Company’s Interim Chief Executive Officer and director, and a significant stockholder of the Company, and Timothy Hart, the Company’s Chief Financial Officer and director, and a significant stockholder of the Company. Under this agreement, we pay TBG a monthly fee of $40,000. In April 2021, we entered into an additional agreement with TBG to provide management services specifically to our Health Karma subsidiary. Under this new agreement, we pay TBG an additional monthly fee of $40,000. During the three months ended June 30, 2021 and 2020, the Company expensed $240,000 and $120,000, respectively, of related party management fees related to these agreements. During the six months ended June 30, 2021 and 2020, the Company expensed $360,000 and $240,000, respectively, of related party management fees related to these agreements.

At June 30, 2021 and December 31, 2020, the Company had prepaid management fees related to the aforementioned agreement with TBG amounting to $465,000 and $480,000, respectively.

MEDIXALL GROUP, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

R3 Accounting LLC (“R3”), owned by Mr. Hart, provides accounting, tax and bookkeeping services to the Company. During the three and six months ended June 30, 2021 and 2020, the Company expensed $65,500 and $103,500 and $135,538 and $141,000, respectively, related to R3 services.

At June 30, 2021 and December 31, 2020, the Company had short term cash advances outstanding due to Turnkey Capital, Inc. (“Turnkey”), a related party of the Company. The advances are due on demand, are unsecured, and do not bear any interest.

During the three and six month period ended June 30, 2021, the Company paid $181,500 and $275,500 in marketing and consulting expenses to two companies which are owned by the president of Turnkey a related party. There was no such fee during the three and six month period ended June 30, 2020.

Prepaid expenses (accounts payable and accrued expenses) to related parties are as follows:


Related Party	At June 30, 2021			At December 31, 2020
TBG	$	465,000		$	480,000
Turnkey		(457,300	)		(457,300	)
R3		(19,931	)		(19,931	)
	$	(12,231	)	$	2,769

EGG Agreement

On September 13, 2019, Turnkey entered into a Definitive Acquisition Agreement with Healthspan Medical Systems, Inc., doing business as EGG Health Hub, Inc. (“EGG”). On October 29, 2020, Turnkey and EGG executed a share exchange agreement in which EGG became a wholly owned subsidiary of Turnkey. Turnkey and EGG are related parties of the Company. EGG does not currently conduct any operations.

EGG is a brand new model for healthcare and wellness that brings together top physicians and wellness professionals into co-practicing communities with shared access to a full-stack technology platform – scheduling, billing, client acquisition, and telemedicine – and flexible access to office space designed to optimize both the physician and client experience. This model creates a compelling new option for re-tenanting traditional shopping centers and mixed-use space.

On July 27, 2020, the Company and Turnkey entered into an agreement in which the Company issued 1,000,000 shares of its common stock to Turnkey in exchange for the exclusive technology rights to develop EGG’s business model (as described in the preceding paragraph) with the Company’s technological infrastructure, including but not limited to the use of the Company’s healthcare website platform. The transaction was accounted for at historical cost as a transaction under common ownership that lacks commercial substance. As such, the issuance of the Company’s common stock to Turnkey was recorded as an increase of $1,000 to common stock, with a corresponding decrease to additional paid-in capital.

Note 6 – Long Term Debt

During May 2020, the Company received a Paycheck Protection Program loan in the amount of $165,719. The Small Business Administration forgave the full amount of the loan in June 2021. Accordingly, the Company has derecognized the loan and recognized the revenue of $165,719 from loan forgiveness.

Note 7 – Legal Contingencies

The Company has received a Subpoena from the SEC requesting certain documents in connection with an investigation styled, “In the Matter of TBG Holdings Corporation”. This investigation is a non-public, fact-finding inquiry and does not require disclosure by the Company. The Company has decided to disclose this matter in order to more fully keep our shareholders apprised of matters affecting the Company and its shareholders. The investigation in no way has made a conclusion that anyone has violated any securities laws or regulations. Also, this investigation does not mean the SEC has a negative opinion of any person, entity, or security. All SEC investigations are conducted privately.

TBG Holdings Corp. (“TBG”) is owned in part by Neil Swartz, the Company’s Interim Chief Executive Officer and Chairman of the Board, and a significant stockholder of the Company, and Timothy Hart, the Company’s Chief Financial Officer, Treasurer, Secretary and director, and a significant stockholder of the Company. Pursuant to an agreement dated June 2013 and amended on May 20, 2019, TBG was engaged to provide business advisory services, manage and direct our public relations, provide recruiting services, develop and maintain material for market makers and investment bankers, provide general administrative services, and respond to incoming investor relations calls. In April, 2021 the Company entered into an additional contract with TBG to provide management services to our wholly-owned subsidiary, Health Karma, Inc. Under these agreements, the Company pays TBG a monthly fee of $80,000. As part of its investigation, the SEC has requested certain financial documents and information related to the Company, as well as documents related to transactions with R3 Accounting LLC (“R3”) and other entities. R3, owned by Mr. Hart, provides accounting, tax, and bookkeeping services to the Company.

As part of its investigation, the SEC has requested certain financial documents and information related to the Company, as well as documents related to transactions with R3, TBG and other entities.

All transactions between the Company and each of TBG and R3 are routinely updated and disclosed in the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, each as filed with the SEC. These filings can be found on the SEC’s public web site at https://www.sec.gov/cgi-bin/browse-edgar?CIK=1601280&owner=exclude. The web site is not incorporated herein by reference and is not a part of this Quarterly Report on Form 10-Q.

The Company is cooperating fully with the SEC in its investigation and has supplied, and if requested, will continue to supply, the SEC with all documents requested in a timely fashion.

To date, the SEC has not informed the Company that it has opened an investigation into the Company and at this time, the Company is not aware of any investigation into the Company by the SEC.

From time to time, the Company may be the subject of pending or threatened legal actions and proceedings, including those that arise in the ordinary course of business. Management is not aware of any material pending legal proceedings, other than ordinary routine litigation incidental to the business, or proceedings known to be contemplated by governmental authorities, to which the Company or any of its subsidiaries is a party or of which any of their property is the subject. As of the date of this Quarterly Report on Form 10-Q, there are no material proceedings to which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or any associate of any such director, officer, affiliate of the Company, or security holder is a party adverse to the Company or any of its subsidiaries or has a material interest adverse to the Company or any of its subsidiaries.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements. Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as “anticipate,” “believe,” “estimate,” “intend,” “could,” “should,” “would,” “may,” “seek,” “plan,” “might,” “will,” “expect,” “predict,” “project,” “forecast,” “potential,” “continue” negatives thereof or similar expressions. Forward-looking statements contained in this report speak only as of the date of this report, are based on various underlying assumptions and current expectations about the future and are not guarantees. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, matters associated with:

	·	our ability to continue as a going concern,
	·	our history of losses which we expect to continue,
	·	the significant amount of liabilities due to related parties,
	·	our ability to raise sufficient capital to fund our company,
	·	our ability to integrate acquisitions and the operations of acquired companies,
	·	the limited experience of our management in the operations of a public company,
	·	potential weaknesses in our internal control over financial reporting,
	·	increased costs associated with reporting obligations as a public company,
	·	a limited market for our common stock and limitations resulting from our common stock being designated as a penny stock,
	·	the ability of our board of directors to issue preferred stock without the consent of our stockholders,
	·	our management controls the voting of our outstanding securities,
	·	the conversion of shares of Series A and B preferred stock will be very dilutive to our existing common stockholders,
	·	risks associated with and unique to health care,
	·	risks associated with stability of the internet, data security, exposure to data breach, and
	·	risks associated with COVID-19

You should read thoroughly this report and the documents that we refer to herein with the understanding that our actual future results may be materially different from and/or worse than what we expect. We qualify all of our forward-looking statements by these cautionary statements, including those made in this report, in Part I. Item 1A. Risk Factors appearing in our Annual Report on Form 10-K for the year ended December 31, 2020 and our other filings with the Securities and Exchange Commission. Other sections of this report include additional factors which could adversely impact our business and financial performance. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events. These forward-looking statements speak only as of the date of this report, and you should not rely on these statements without also considering the risks and uncertainties associated with these statements and our business.

OTHER PERTINENT INFORMATION

Unless specifically set forth to the contrary, when used in this report the terms “MediXall Group”, the “Company,” “we”, “us”, “our” and similar terms refer to MediXall Group, Inc., a Nevada corporation, and its wholly-owned subsidiaries.

GENERAL

The following Management’s Discussion and Analysis (“MD&A”) is intended to help the reader understand the Company’s results of operations and financial condition. The MD&A is provided as a supplement to, and should be read in conjunction with the unaudited condensed consolidated financial statements and the accompanying notes included in this Quarterly Report on Form 10-Q.

The MD&A is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and related disclosure of contingent assets and liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

OVERVIEW

MediXall is a technology and innovation-driven organization that is developing a new generation healthcare marketplace platform seeking to address the growing needs of self-pay and high deductible consumers for greater transparency and price competition in their healthcare costs. The cloud-based MediXall.com platform seeks to connect patients with healthcare providers and wellness services. The Company’s targeted marketplace is Florida, with plans for a nationwide roll-out.

MediXall seeks to revolutionize the medical industry by improving communication; providing better technology and support services; and enabling more efficient, cost-effective healthcare for the consumer. By approaching the healthcare ecosystem as a whole, MediXall seeks to create, invest and incubate companies that embody its mission statement.

The Company expanded its MediXall platform to include Health Karma. Health Karma™ is planned to be an end-to-end free healthcare navigation platform that helps consumers make simpler, smarter healthcare decisions regardless of health insurance status. Health Karma offers an information driven solution that pairs transparency with personalization to deliver smarter savings at every turn, enabling users to get the most from their health insurance plan.

Thus far, MediXall has launched the MediXall platform marketplace throughout Florida beginning in 2019 in a controlled launch and launched Health Karma throughout the U.S. in a beta release beginning in August 2020 and a nationwide public launch in November 2020. The Company generated minimal revenue in 2021 and no revenue in 2020 as its online healthcare platform is still in the application and development stage.

Going Concern

We have incurred net losses of approximately $22.6 million since inception through June 30, 2021. The report of our independent registered public accounting firm on our consolidated financial statements for the year ended December 31, 2020 contains an explanatory paragraph regarding our ability to continue as a going concern based upon the fact that we are dependent upon our ability to increase revenues along with raising additional external capital as needed. These factors, among others, raise substantial doubt about our ability to continue as a going concern. Our condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. There are no assurances we will be successful in our efforts to generate revenues or report profitable operations or to continue as a going concern, in which event investors would lose their entire investment in our company.

Results of Operations

Three Month Period Ended June 30, 2021 Compared to the Three Month Period Ended June 30, 2020

Revenue

We had revenue of $166,642 for the three months ended June 30, 2021 and no revenue for the three months ended June 30, 2020. The revenue was driven mainly from Paycheck Protection Program loan forgiveness.

Operating Expenses

A summary of our operating expense for the three month periods ended June 30, 2021 and 2020 follows:

	Three Months Ended
	June 30,				Increase /
	2021		2020		(Decrease)
Operating expense
Professional fees	$	342,080	$	257,177	$	84,903
Professional fees – related party		247,000		103,500		143,500
Management fee – related party		240,000		120,000		120,000
Personnel related expenses		682,361		608,337		74,024
Other selling, general, and administrative		314,417		56,996		257,421
Total operating expense	$	1,825,858	$	1,146,010	$	679,848

Operating expenses increased $679,848, or 59%, to $1,825,858 during the three months ended June 30, 2021 compared to $1,146,010 during the same period in 2020. The increase in total operating expenses is primarily due to:

	(1)	An increase in professional fees of $84,903 which primarily resulted from the Company issuing shares of its restricted common stock for consulting services during the three month period ended June 30, 2021. There were no such share issuances during the three month period ended June 30, 2020.

	(2)	Professional fees – related party increased by $143,500 or 139%, due to marketing and consulting expenses to two companies which are owned by the president of Turnkey a related party during the three month period ended June 30, 2021. There was no such expense during the three month period ended June 30, 2020. This increase was slightly offset by a decrease in R3 service fees during the three month period ended June 30, 2021 compared to the same period in 2020.

	(3)	The increase in management fees - related party of $120,000 is due to an additional contract entered into with TBG to provide management services to our wholly-owned subsidiary, Health karma, Inc. There was no such contract during the three month period ended June 20, 2020.

	(4)	The increase in personnel related expenses of $74,024 is due to issuing shares of its restricted common stock for employee services during the three month period ended June 30, 2020. There were no such share issuances during the three month period ended June 30, 2021.

	(5)	Other selling, general, and administrative increased by $257,421 or 452% due to an increase in business development and marketing expenses during the three month period ended June 30, 2021.

We expect expenses to increase as we move forward with further enhancing the platform.

Six Month Period Ended June 30, 2021 Compared to the Six Month Period Ended June 30, 2020

Revenue

We had revenue of $169,913 for the six months ended June 30, 2021 and no revenue for the six months ended June 30, 2020. The revenue was driven mainly from Paycheck Protection Program loan forgiveness.

Operating Expenses

A summary of our operating expense for the six month periods ended June 30, 2021 and 2020 follows:

	Six Months Ended
	June 30,				Increase /
	2021		2020		(Decrease)
Operating expense
Professional fees	$	681,660	$	904,441	$	(222,781	)
Professional fees – related party		411,038		141,000		270,038
Management fee – related party		360,000		240,000		120,000
Personnel related expenses		1,283,911		1,569,827		(285,916	)
Other selling, general, and administrative		424,821		141,827		282,994
Total operating expense	$	3,161,430	$	2,997,095	$	164,335

Operating expenses increased $164,335, or 5%, to $3,161,430 during the six months ended June 30, 2021 compared to $2,997,095 during the same period in 2020. The decrease in total operating expenses is primarily due to:

	(1)	A decrease in professional fees of $222,781 which primarily resulted from fewer shares of stock issued for services for the six months ended June 30, 2020 compared to the six months ended June 30, 2021.

	(2)	Professional fees – related party increased by $270,038 or 192%, due to marketing and consulting expenses to two companies which are owned by the president of Turnkey a related party during the six month period ended June 30, 2021. There was no such expense during the six month period ended June 30, 2020. This increase was slightly offset by a decrease in R3 service fees during the six month period ended June 30, 2021 compared to the same period in 2020.

	(3)	The increase in management fees - related party of $120,000 is due to an additional contract entered into with TBG to provide management services to our wholly-owned subsidiary, Health karma, Inc. There was no such contract during the three month period ended June 20, 2020.

	(4)	The decrease in personnel related expenses of $285,916 which is due to issuing shares of its restricted common stock for employee services during the six month period ended June 30, 2020 in excess of that issued in the same period of 2021.

	(5)	Other selling, general, and administrative increased by $282,994 or 200% due to an increase in business development and marketing expenses during the six month period ended June 30, 2021.

We expect expenses to increase as we move forward with further enhancing the platform.

Liquidity and capital resources

Liquidity is the ability of a company to generate sufficient cash to satisfy its needs. At June 30, 2021, we had $125,354 in cash and net negative working capital of $119,806.

For the six month period ended June 30, 2021, we raised $2,294,375 from sales of our restricted common stock and preferred stock, and for the six month period ended June 30, 2020, we raised $1,598,750.

Net cash used in operating activities for six month period ended June 30, 2021 was $2,801,943, as compared to $1,611,234 for the six month period ended June 30, 2020. This change primarily results from our decreased net loss, offset by fluctuations in accounts payable and accrued expenses, accounts payable and accrued expenses-related party and the issuance of common stock for services rendered.

Our primary source of capital to develop and implement our business plan has been from sales of common and preferred stock.

Other Contractual Obligations

None.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term "off-balance sheet arrangement" generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with us is a party, under which we have any obligation arising under a guarantee contract, derivative instrument or variable interest or a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

Critical Accounting Policies

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.

Risks and Uncertainties

The Company's operations are subject to significant risks and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure. Additionally, the Company faces risk and uncertainty related to the COVID-19 pandemic.

Share Based Payment Arrangements

The Company applies the fair value method in accounting for its stock-based compensation. This standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company fair values the stock-based compensation at the market price for the Company's stock as of the date of issuance.

Recoverability of Long-Lived Assets

The Company assesses the recoverability of long-lived assets annually or whenever events or changes in circumstances indicate that expected future undiscounted cash flows might not be sufficient to support the carrying amount of an asset. The Company deems an asset to be impaired if a forecast of undiscounted future operating cash flows is less than the carrying amount. If an asset is determined to be impaired, the loss is measured as the amount by which the carrying value of the asset exceeds its fair value. There was no impairment of long-lived assets pertaining to the six month periods ended June 30, 2021 and 2020. However, there can be no assurances that future impairment tests will not result in a charge to operations.

Website and Development Costs

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.

ITEM 4. CONTROLS AND PROCEDURES.

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

We carried out an evaluation as required by paragraph (b) of Rule 13a-15 and 15d-15 of the Exchange Act, under the supervision and with the participation of our management, including our Interim Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of June 30, 2021.

A material weakness can be defined as an insufficiency of internal controls that may result in a more than remote likelihood that a material misstatement will not be prevented, detected or corrected in a company’s condensed consolidated financial statements.

Based upon that evaluation, our Interim Chief Executive Officer and Chief Financial Officer concluded that as of June 30, 2021, our disclosure controls and procedures were not effective, based on the following deficiencies:

	·	Weaknesses in accounting and finance personnel: We have a small accounting staff and we do not have the robust employee resources and expertise needed to meet complex and intricate GAAP and SEC reporting requirements of a U.S. public company. Additionally, numerous adjustments and proposed adjustments have been noted by our auditors. This is deemed by management to be a material weakness in preparing condensed consolidated financial statements.

	·	We have written accounting policies and control procedures, but we do not have sufficient staff to implement the related controls. Management had determined that this lack of the implantation of segregation of duties, as required by our written procedures, represents a material weakness in our internal controls.

	·	Internal control has as its core a basic tenant of segregation of duties. Due to our limited size and economic constraints, the Company is not able to segregate for control purposes various asset control and recording duties and functions to different employees. This lack of segregation of duties had been evaluated by management, and has been deemed to be a material control deficiency.

The Company has determined that the above internal control weaknesses and deficiencies could result in a reasonable possibility for the condensed consolidated financial statements that a material misstatement will not be prevented or detected on a timely basis by the Company’s internal controls.

Management is currently evaluating what steps can be taken in order to address these material weaknesses. As a growing small business, the Company continuously devotes resources to the improvement of our internal control over financial reporting. Due to budget constraints, the staffing size, proficiency and specific expertise in the accounting department is below requirements for the operation. The Company is anticipating correcting deficiencies as funds become available.

Changes in Internal Control Over Financial Reporting

There were no changes during our last fiscal quarter that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

The Company has received a Subpoena from the Securities and Exchange Commission (the “SEC”) requesting certain documents in connection with an investigation styled, “In the Matter of TBG Holdings Corporation”. This investigation is a non-public, fact-finding inquiry and does not require disclosure by the Company. The Company has decided to disclose this matter in order to more fully keep our shareholders apprised of matters affecting the Company and its shareholders. The investigation in no way has made a conclusion that anyone has violated any securities laws or regulations. Also, this investigation does not mean the SEC has a negative opinion of any person, entity, or security. All SEC investigations are conducted privately.

The Company is cooperating fully with the SEC in its investigation and has supplied, and if requested, will continue to supply, the SEC with all documents requested in a timely fashion.

To date, the SEC has not informed the Company that it has opened an investigation into the Company and at this time, the Company is not aware of any investigation into the Company by the SEC.

ITEM 1A. RISK FACTORS.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

During the six month period ended June 30, 2021, we:

	·	Received proceeds of $949,375, net of offering costs of $0, pursuant to a Private Placement Memorandum and for which 3,797,550 shares of restricted common stock were issued. These securities were issued pursuant to exemptions from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) thereof.

	·	Received proceeds of $1,345,000, net of offering costs of $0, pursuant to a Private Placement Memorandum and for which 1,345,000 shares of restricted Series B preferred stock were issued. These securities were issued pursuant to exemptions from the registration requirements of the Securities Act pursuant to Section 4(a)(2) thereof.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable to our Company.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.

Exhibit No.		Description
31.1		Rule 13a-14(a)/ 15d-14(a) Certification of Interim Chief Executive Officer *
31.2		Rule 13a-14(a)/ 15d-14(a) Certification of Chief Financial Officer*
32.1		Section 1350 Certification of Interim Chief Executive Officer *
32.2		Section 1350 Certification of Chief Financial Officer *
101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) *
101.SCH		Inline XBRL Taxonomy Extension Schema Document *
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document *
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document *
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document *
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document *
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

———————

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MediXall Group, Inc.

Dated: September 30, 2021	By:	/s/ Timothy S. Hart
		Timothy S. Hart
		Chief Financial Officer (Principal Financial and Accounting Officer)


Dated: September 30, 2021	By:	/s/ Neil Swartz
		Neil Swartz
		Interim Chief Executive Officer (Principal Executive Officer)

EX-31.1 2 mdxl_ex31z1.htm CERTIFICATIONS

Exhibit 31.1

CERTIFICATIONS

I, Neil Swartz, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended June 30, 2021 of MediXall Group, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the year covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: September 30, 2021

/s/ Neil Swartz

Neil Swartz

Interim Chief Executive Officer

(principal executive officer)

EX-31.2 3 mdxl_ex31z2.htm CERTIFICATIONS

Exhibit 31.2

CERTIFICATIONS

I, Timothy S. Hart, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended June 30, 2021 of MediXall Group, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: September 30, 2021

/s/ Timothy S. Hart

Timothy S. Hart

Chief Financial Officer

(principal financial officer)

EX-32.1 4 mdxl_ex32z1.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of MediXall Group, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Neil Swartz, Interim Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: September 30, 2021	/s/ Neil Swartz
	Neil Swartz
	Interim Chief Executive Officer
	(principal executive officer)

EX-32.2 5 mdxl_ex32z2.htm CERTIFICATION

Exhibit 32.2

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of MediXall Group, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Timothy S. Hart, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: September 30, 2021	/s/ Timothy S. Hart
	Timothy S. Hart
	Chief Financial Officer
	(principal financial officer)

EX-101.SCH 6 mdxl-20210630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Organization and Nature of Operation link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Preferred Stock link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Long Term Debt link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Legal Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Significant Accounting Policies (Schedule of Basic and Diluted EPS) (Details) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies (Schedule of potentially dilutive securities) (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Preferred Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Long Term Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Legal Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 mdxl-20210630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 mdxl-20210630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 mdxl-20210630_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Equity Components [Axis] Series A Voting Preferred Stock [Member] Series B Voting Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Preferred Stock [Member] Related Party [Axis] T B G [Member] R3 Accounting LLC [Member] T B G Holdings Corp [Member] Turnkey [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS CURRENT ASSETS: Cash Prepaid expenses - related party Other assets Total current assets Furniture and equipment, net Right-of-use-operating lease asset Website and development costs Total assets LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable and accrued expenses Accounts payable and accrued expenses - related party Operating lease liability Note payable Total current liabilities Note payable, net of current portion Total liabilities STOCKHOLDERS' EQUITY: Preferred Stock, Value, Issued Common Stock, $0.001 par value 750,000,000 shares authorized; 105,389,180 and 98,898,130 shares issued and outstanding Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Convertible Preferred stock, par value (in dollars per share) Convertible Preferred stock, shares authorized Convertible Preferred stock, shares issued Convertible Preferred stock, shares outstanding Common Stock, Par value (in dollars per share) Common Stock, shares authorized Common Stock, shares issued Common Stock, shares outstanding Income Statement [Abstract] Revenue Operating Expenses Professional fees Professional fees - related party Management fees - related party Personnel related expenses Other selling, general and administrative Total Operating Expenses Loss before income taxes Income taxes Net loss Less preferred stock dividends Net loss to common shareholders Net loss per common share - basic and diluted Weighted average number of common shares outstanding during the periods - basic and diluted Beginning balance, value Beginning balance shares Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs (unaudited) Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs (unaudited), Shares Proceeds received from sale of Preferred Stock (unaudited) Proceeds received from sale of Preferred Stock (unaudited), Shares Proceeds received from sale of Preferred Stock (unaudited) Proceeds received from sale of Preferred Stock,shares Common stock issued for services (unaudited) Common stock issued for services (unaudited), Shares Net loss (unaudited) Ending balance, value Ending balance shares Offering costs Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Common stock issued as compensation for services Gain from forgiveness of note payable Changes in operating assets and liabilities: Prepaid expenses- related party Other assets Accounts payable and accrued expenses Accounts payable and accrued expenses - related party Amortization of right-of-use operating lease asset Operating lease liability Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of furniture and equipment Website development costs Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from the sale of common stock, net of offering costs Proceeds from the sale of preferred stock Proceeds from note payable Net cash provided by financing activities Net (decrease) increase in cash Cash at beginning of period Cash at end of period Supplemental disclosures of non-cash information Decrease in note payable resulting from gain on forgiveness of note payable Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Nature of Operation Going Concern Accounting Policies [Abstract] Summary of Significant Accounting Policies Equity [Abstract] Preferred Stock Related Party Transactions [Abstract] Related Party Transactions Debt Disclosure [Abstract] Long Term Debt Commitments and Contingencies Disclosure [Abstract] Legal Contingencies Basis of Presentation Principles of Consolidation Use of Estimates Subsequent Events Risks and Uncertainties Income Taxes Revenue Recognition Share-Based Payment Arrangements Loss Per Share Recoverability of Long-Lived Assets Website and Development Costs Allowance for Uncollectible Accounts Receivable EX-101.PRE 10 mdxl-20210630_pre.xml XBRL PRESENTATION FILE XML 11 mdxl_10q-063021_htm.xml IDEA: XBRL DOCUMENT 0001601280 2021-01-01 2021-06-30 0001601280 2021-09-30 0001601280 2021-06-30 0001601280 2020-12-31 0001601280 us-gaap:SeriesAPreferredStockMember 2021-06-30 0001601280 us-gaap:SeriesAPreferredStockMember 2020-12-31 0001601280 us-gaap:SeriesBPreferredStockMember 2021-06-30 0001601280 us-gaap:SeriesBPreferredStockMember 2020-12-31 0001601280 2021-04-01 2021-06-30 0001601280 2020-04-01 2020-06-30 0001601280 2020-01-01 2020-06-30 0001601280 mdxl:SeriesAVotingPreferredStockMember 2019-12-31 0001601280 mdxl:SeriesBVotingPreferredStockMember 2019-12-31 0001601280 us-gaap:CommonStockMember 2019-12-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001601280 us-gaap:RetainedEarningsMember 2019-12-31 0001601280 2019-12-31 0001601280 mdxl:SeriesAVotingPreferredStockMember 2020-01-01 2020-03-31 0001601280 mdxl:SeriesBVotingPreferredStockMember 2020-01-01 2020-03-31 0001601280 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001601280 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001601280 2020-01-01 2020-03-31 0001601280 mdxl:SeriesAVotingPreferredStockMember 2020-03-31 0001601280 mdxl:SeriesBVotingPreferredStockMember 2020-03-31 0001601280 us-gaap:CommonStockMember 2020-03-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001601280 us-gaap:RetainedEarningsMember 2020-03-31 0001601280 2020-03-31 0001601280 mdxl:SeriesAVotingPreferredStockMember 2020-04-01 2020-06-30 0001601280 mdxl:SeriesBVotingPreferredStockMember 2020-04-01 2020-06-30 0001601280 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001601280 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001601280 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001601280 mdxl:SeriesAVotingPreferredStockMember 2020-06-30 0001601280 mdxl:SeriesBVotingPreferredStockMember 2020-06-30 0001601280 us-gaap:CommonStockMember 2020-06-30 0001601280 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001601280 us-gaap:RetainedEarningsMember 2020-06-30 0001601280 2020-06-30 0001601280 mdxl:SeriesAVotingPreferredStockMember 2020-12-31 0001601280 mdxl:SeriesBVotingPreferredStockMember 2020-12-31 0001601280 us-gaap:CommonStockMember 2020-12-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001601280 us-gaap:RetainedEarningsMember 2020-12-31 0001601280 mdxl:SeriesAVotingPreferredStockMember 2021-01-01 2021-03-31 0001601280 mdxl:SeriesBVotingPreferredStockMember 2021-01-01 2021-03-31 0001601280 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001601280 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001601280 2021-01-01 2021-03-31 0001601280 mdxl:SeriesAVotingPreferredStockMember 2021-03-31 0001601280 mdxl:SeriesBVotingPreferredStockMember 2021-03-31 0001601280 us-gaap:CommonStockMember 2021-03-31 0001601280 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001601280 us-gaap:RetainedEarningsMember 2021-03-31 0001601280 2021-03-31 0001601280 mdxl:SeriesAVotingPreferredStockMember 2021-04-01 2021-06-30 0001601280 mdxl:SeriesBVotingPreferredStockMember 2021-04-01 2021-06-30 0001601280 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001601280 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001601280 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001601280 mdxl:SeriesAVotingPreferredStockMember 2021-06-30 0001601280 mdxl:SeriesBVotingPreferredStockMember 2021-06-30 0001601280 us-gaap:CommonStockMember 2021-06-30 0001601280 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001601280 us-gaap:RetainedEarningsMember 2021-06-30 0001601280 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001601280 us-gaap:PreferredStockMember 2021-01-01 2021-06-30 0001601280 us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-06-30 0001601280 us-gaap:SeriesAPreferredStockMember 2020-04-01 2020-06-30 0001601280 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-06-30 0001601280 us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-06-30 0001601280 us-gaap:SeriesBPreferredStockMember 2021-04-01 2021-06-30 0001601280 us-gaap:SeriesBPreferredStockMember 2020-04-01 2020-06-30 0001601280 us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-06-30 0001601280 us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-06-30 0001601280 us-gaap:SeriesBPreferredStockMember 2020-06-24 0001601280 mdxl:TBGMember 2021-01-01 2021-06-30 0001601280 2021-04-01 2021-04-30 0001601280 mdxl:TBGMember 2021-04-01 2021-06-30 0001601280 mdxl:TBGMember 2020-04-01 2020-06-30 0001601280 mdxl:TBGMember 2021-06-30 0001601280 mdxl:TBGMember 2020-12-31 0001601280 mdxl:R3AccountingLLCMember 2021-04-01 2021-06-30 0001601280 mdxl:R3AccountingLLCMember 2020-04-01 2020-06-30 0001601280 mdxl:R3AccountingLLCMember 2021-01-01 2021-06-30 0001601280 mdxl:R3AccountingLLCMember 2020-01-01 2020-06-30 0001601280 mdxl:TBGHoldingsCorpMember 2021-06-30 0001601280 mdxl:TBGHoldingsCorpMember 2020-12-31 0001601280 mdxl:TurnkeyMember 2021-06-30 0001601280 mdxl:TurnkeyMember 2020-12-31 0001601280 mdxl:R3AccountingLLCMember 2021-06-30 0001601280 mdxl:R3AccountingLLCMember 2020-12-31 0001601280 mdxl:TurnkeyMember 2020-07-01 2020-07-27 0001601280 mdxl:TurnkeyMember 2021-01-01 2021-06-30 0001601280 2021-05-01 2021-05-31 0001601280 2021-06-01 2021-06-30 iso4217:USD shares iso4217:USD shares pure 0001601280 false --12-31 2021 Q2

10-Q true 2021-06-30 false 333-194337 MediXall Group, Inc. NV 33-0864127 2929 East Commercial Blvd. PH-D Ft. Lauderdale FL 33308 954 440-4678 Yes Yes Non-accelerated Filer true false true 106148845

125354

645762

465000

480000

8000

590354

1133762

23696

26536

7003

43757

452244

439404

1073297

1643459

224436

571405

477231

8493

47200

25373

710160

1121209

140346

710160

1261555

0.001

1000000

264894

265

0.001

4000000

2984360

1639360

2984

1639

0.001

750000000

105389180

98898130

105389

98898

22827832

19862918

-22573333

-19581816

363137

381904

1073297

1643459

166642

169913

342080

257177

681660

904441

247000 103500 411038 141000 240000 120000 360000 240000

682361

608337

1283911

1569827

314417

56996

424821

141827

1825858

1146010

3161430

2997095

-1659216

-1146010

-2991517

-2997095

-1659216

-1146010

-2991517

-2997095

59687

106656

-1718903

-1146010

-3098173

-2997095

-0.02

-0.01

-0.03

102075557

87751941

101177844

86211828

264894

265

80952554

80953

13966326

-13649784

397760

1907000

1907

499843

501750

3964376

3964

1039101

1043065

-1851085

264894

265

86823930

86824

15505270

-15500869

91490

3000

2350000

2350

594650

597000

500000

500

499500

500000

1880000

1880

468120

470000

-1146010

264894

265

500000

500

91053930

91054

17067540

-16646879

512480

264894

265

1639360

1639

98898130

98898

19862918

-19581816

381904

2487550

2488

619387

621875

1345000 1345 1343655 1345000

-1332301

264894

265

2984360

2984

101385680

101386

21825960

-20914117

1016478

1290000

1289

326211

327500

2713500

2714

675661

678375

-1659216

264894

265

2984360

2984

105389180

105389

22827832

-22573333

363137

-2991517

-2997095

2840

2000

678375

1513065

165719

-15000

45430

-8000

-346969

157720

-241870

36754

34302

-38707

-33926

-2801943

-1611234

-12429

12840

14600

-12840

-27029

949375

1098750

1345000

500000

165720

2294375

1764470

-520408

126207

645762

446219

125354

572426

-165719

Note 1 - Organization and Nature of Operation MediXall Group, Inc. (the "Company “or “MediXall”) was incorporated on December 21, 1998 under the laws of the State of Nevada under the name of IP Gate, Inc. The Company had various name changes since, to reflect changes in the Company’s operating strategies. MediXall is a technology and innovation-driven organization that has developed a new generation healthcare marketplace platform to address the growing needs of self-pay and high deductible consumers for greater transparency and price competition in their healthcare costs. The cloud-based MediXall.com platform connects patients with healthcare providers and wellness services. The Company’s targeted marketplace is Florida, with plans for a nationwide roll-out. Thus far, MediXall has launched the MediXall platform marketplace throughout Florida beginning in 2019 in a controlled launch and launched Health Karma throughout the U.S. in a beta release beginning in August 2020 and nationwide public launch in November 2020. The Company generated minimal revenue in 2021 and no revenue in 2020 as its online healthcare platform is still in the application and development stage. The revenue recognized in 2021 was driven almost entirely from the Paycheck Protection Program loan forgiveness. Further discussion on our operations, mission, and initiatives can be found in the Management’s Discussion and Analysis section of this report. The Company has the following wholly-owned subsidiaries: (1) IHL of Florida, Inc., which is dormant, (2) Medixall Financial Group, which is dormant, (3) Medixaid, Inc., and (4) MediXall.com, Inc., which were established to carry out the development and operation of our healthcare marketplace platform, and (5) Health Karma, Inc. which was established in 2020 to increase functionality of the MediXall platform.

Note 2 – Going Concern The Company has an accumulated deficit of $22,573,333 at June 30, 2021, and does not have sufficient operating cash flows. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplates continuation of the Company as a going concern, which is dependent upon the Company’s ability to establish itself as a profitable business. Since the Company has generated minimal revenues from its planned operations, its ability to continue as a going concern is wholly dependent upon its ability to obtain additional financing. Since inception, the Company has funded operations through short-term borrowings, related party loans, and the proceeds from equity sales in order to meet its strategic objectives. The Company's future operations are dependent upon its ability to generate revenues along with additional external funding as needed. However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of its business plan. Subsequent to June 30, 2021, the Company has issued 1,499,040 common shares and 665,000 preferred shares for total proceeds of $404,666 and $665,000, respectively. In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. These unaudited condensed consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying unaudited condensed consolidated financial statements. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

-22573333

1499040

665000

404666

665000

Note 3 - Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited, condensed consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information, and the SEC rules for interim financial reporting. Certain information and footnote disclosures normally included in the condensed consolidated financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations. However, in the opinion of management, the accompanying interim condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the Company’s condensed consolidated financial position as of June 30, 2021 and the condensed consolidated results of operations and cash flows for the periods presented. The condensed consolidated results of operations for interim periods are not necessarily indicative of the results of operations to be expected for any subsequent interim period or for the fiscal year ending December 31, 2021. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on June 17, 2021. Principles of Consolidation These unaudited condensed consolidated financial statements presented are those of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates. A material estimate that is particularly susceptible to significant change in the near-term relate to the determination of the impairment of website and development cost. The Company uses various assumptions and actuarial data it believes to be reasonable under the circumstances to make this estimate. Although considerable variability is likely to be inherent in this estimate, management believes that the amount provided is reasonable. This estimate is continually reviewed and adjusted if necessary. Such adjustments are reflected in current operations. Subsequent Events Management has evaluated events occurring subsequent to the unaudited condensed consolidated balance sheet date, through September 30, 2021, which is the date the unaudited condensed consolidated financial statements were issued, determining all subsequent events have been disclosed. Risks and Uncertainties The Company's operations are subject to significant risks and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure. Additionally, the Company faces significant risk and uncertainty related to the coronavirus global pandemic (“COVID-19”) pandemic. Income Taxes The Company accounts for income taxes using the liability method prescribed by the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification 740, "Income Taxes". Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the year that includes the enactment date. Pursuant to accounting standards related to the accounting for uncertainty in income taxes, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more- likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than -not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de- recognized in the first subsequent financial reporting period in which the threshold is no longer met. The accounting standard also provides guidance on de- recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. The Company assessed its earnings history, trends, and estimates of future earnings, and determined that the deferred tax asset could not be realized as of June 30, 2021. Accordingly, a valuation allowance was recorded against the net deferred tax asset. Revenue Recognition The Company had minimal revenues in 2021 and no revenue in 2020. The Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation. Share-Based Payment Arrangements The Company applies the fair value method in accounting for its stock-based compensation. This standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company values the stock-based compensation at the market price for the Company's stock as of the date of issuance. Loss Per Share The computation of basic loss per share (“LPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted LPS is based on the number of basic weighted-average shares outstanding. The computation of diluted LPS does not assume conversion, exercise or contingent issuance of securities that would have an antidilutive effect on LPS. Therefore, when calculating LPS, there is no inclusion of dilutive securities as their inclusion in the LPS calculation is antidilutive. Following is the computation of basic and diluted loss per share for the three and month periods ended June 30, 2021 and 2020: <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zIU9t6faAsuc" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Schedule of Basic and Diluted EPS) (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td>Schedule of computation of basic and diluted net loss per share</td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20210401__20210630_zexecJFYBGQh" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20200401__20200630_zcCJa1uNWyWe" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20210101__20210630_zHe9zlIWuNcf" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20200101__20200630_zxa11AjeCRt7" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 8pt Times New Roman, Times, Serif"> </td> <td colspan="7" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</td><td style="font: bold 8pt Times New Roman, Times, Serif"> </td> <td colspan="7" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center">Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">June 30,</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">June 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2020</td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Basic and Diluted LPS Computation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--NumeratorAbstract_i01B" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_i02_pp0p0_z2HEMxQqgenh" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 1pt">Loss available to common stockholders</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(1,718,903</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(1,146,010</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(3,098,173</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(2,997,095</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DenominatorAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font: 10pt Times New Roman, Times, Serif">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i01_pdd" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Weighted average number of common shares outstanding</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">102,075,557</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">87,751,941</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">101,177,844</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">86,211,828</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--EarningsPerShareBasicAndDiluted_i01_pdd" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Basic and diluted LPS</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.02</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.01</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.03</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.03</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> Potentially dilutive securities not included in the calculation of diluted LPS attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zYFEgYHisrj1" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Schedule of potentially dilutive securities) (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Schedule of potentially dilutive securities not included in the calculation of diluted net loss per share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left">Series A Preferred stock (convertible)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zY7DzrAM0HCk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Preferred stock (convertible)">24,900,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zS7BiJWJssGb" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Preferred stock (convertible)">24,900,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Preferred stock (convertible)">24,900,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Preferred stock (convertible)">24,900,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Series B Preferred stock (convertible)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zRCPlawWWAhd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Preferred stock (convertible)">11,937,440</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zDosZJjTkEa6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Preferred stock (convertible)">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Preferred stock (convertible)">11,937,440</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Preferred stock (convertible)">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> Recoverability of Long-Lived Assets The Company assesses the recoverability of long-lived assets annually or whenever events or changes in circumstances indicate that expected future undiscounted cash flows might not be sufficient to support the carrying amount of an asset. The Company deems an asset to be impaired if a forecast of undiscounted future operating cash flows is less than the carrying amount. If an asset is determined to be impaired, the loss is measured as the amount by which the carrying value of the asset exceeds its fair value. There was no impairment of long-lived assets pertaining to the three and six month periods ended June 30, 2021 and 2020. However, there can be no assurances that future impairment tests will not result in a charge to operations. Website and Development Costs Internal and external costs incurred to develop, the internal-use computer software during the application and development stage shall be capitalized subsequent to the preliminary project stage and when it is probable that the project will be completed. As of June 30, 2021, the Company has met the capitalization requirements and has incurred $452,244 in costs related to the development of the MediXall platform. Allowance for Uncollectible Accounts Receivable An allowance for uncollectible accounts receivable is recorded when management believes the uncollectability of the accounts receivable is confirmed. Subsequent recoveries, if any, are credited to the allowance. The allowance is determined based on management’s review of the debtor’s ability to repay and repayment history, aging history, and estimated value of collateral, if any.

Basis of Presentation The accompanying unaudited, condensed consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information, and the SEC rules for interim financial reporting. Certain information and footnote disclosures normally included in the condensed consolidated financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations. However, in the opinion of management, the accompanying interim condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the Company’s condensed consolidated financial position as of June 30, 2021 and the condensed consolidated results of operations and cash flows for the periods presented. The condensed consolidated results of operations for interim periods are not necessarily indicative of the results of operations to be expected for any subsequent interim period or for the fiscal year ending December 31, 2021. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on June 17, 2021.

Principles of Consolidation These unaudited condensed consolidated financial statements presented are those of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated.

Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates. A material estimate that is particularly susceptible to significant change in the near-term relate to the determination of the impairment of website and development cost. The Company uses various assumptions and actuarial data it believes to be reasonable under the circumstances to make this estimate. Although considerable variability is likely to be inherent in this estimate, management believes that the amount provided is reasonable. This estimate is continually reviewed and adjusted if necessary. Such adjustments are reflected in current operations.

Subsequent Events Management has evaluated events occurring subsequent to the unaudited condensed consolidated balance sheet date, through September 30, 2021, which is the date the unaudited condensed consolidated financial statements were issued, determining all subsequent events have been disclosed.

Risks and Uncertainties The Company's operations are subject to significant risks and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure. Additionally, the Company faces significant risk and uncertainty related to the coronavirus global pandemic (“COVID-19”) pandemic.

Income Taxes The Company accounts for income taxes using the liability method prescribed by the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification 740, "Income Taxes". Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the year that includes the enactment date. Pursuant to accounting standards related to the accounting for uncertainty in income taxes, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more- likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than -not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de- recognized in the first subsequent financial reporting period in which the threshold is no longer met. The accounting standard also provides guidance on de- recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. The Company assessed its earnings history, trends, and estimates of future earnings, and determined that the deferred tax asset could not be realized as of June 30, 2021. Accordingly, a valuation allowance was recorded against the net deferred tax asset.

Revenue Recognition The Company had minimal revenues in 2021 and no revenue in 2020. The Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation.

Share-Based Payment Arrangements The Company applies the fair value method in accounting for its stock-based compensation. This standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company values the stock-based compensation at the market price for the Company's stock as of the date of issuance.

Loss Per Share The computation of basic loss per share (“LPS”) is based on the weighted average number of shares that were outstanding during the period, including shares of common stock that are issuable at the end of the reporting period. The computation of diluted LPS is based on the number of basic weighted-average shares outstanding. The computation of diluted LPS does not assume conversion, exercise or contingent issuance of securities that would have an antidilutive effect on LPS. Therefore, when calculating LPS, there is no inclusion of dilutive securities as their inclusion in the LPS calculation is antidilutive. Following is the computation of basic and diluted loss per share for the three and month periods ended June 30, 2021 and 2020: <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zIU9t6faAsuc" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Schedule of Basic and Diluted EPS) (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td>Schedule of computation of basic and diluted net loss per share</td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20210401__20210630_zexecJFYBGQh" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20200401__20200630_zcCJa1uNWyWe" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20210101__20210630_zHe9zlIWuNcf" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20200101__20200630_zxa11AjeCRt7" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 8pt Times New Roman, Times, Serif"> </td> <td colspan="7" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</td><td style="font: bold 8pt Times New Roman, Times, Serif"> </td> <td colspan="7" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center">Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">June 30,</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">June 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2020</td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Basic and Diluted LPS Computation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--NumeratorAbstract_i01B" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_i02_pp0p0_z2HEMxQqgenh" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 1pt">Loss available to common stockholders</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(1,718,903</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(1,146,010</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(3,098,173</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(2,997,095</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DenominatorAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font: 10pt Times New Roman, Times, Serif">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i01_pdd" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Weighted average number of common shares outstanding</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">102,075,557</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">87,751,941</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">101,177,844</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">86,211,828</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--EarningsPerShareBasicAndDiluted_i01_pdd" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Basic and diluted LPS</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.02</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.01</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.03</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.03</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> Potentially dilutive securities not included in the calculation of diluted LPS attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zYFEgYHisrj1" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Schedule of potentially dilutive securities) (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Schedule of potentially dilutive securities not included in the calculation of diluted net loss per share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left">Series A Preferred stock (convertible)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zY7DzrAM0HCk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Preferred stock (convertible)">24,900,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zS7BiJWJssGb" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Preferred stock (convertible)">24,900,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Preferred stock (convertible)">24,900,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Preferred stock (convertible)">24,900,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Series B Preferred stock (convertible)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zRCPlawWWAhd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Preferred stock (convertible)">11,937,440</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zDosZJjTkEa6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Preferred stock (convertible)">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Preferred stock (convertible)">11,937,440</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Preferred stock (convertible)">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zIU9t6faAsuc" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Schedule of Basic and Diluted EPS) (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td>Schedule of computation of basic and diluted net loss per share</td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20210401__20210630_zexecJFYBGQh" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20200401__20200630_zcCJa1uNWyWe" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20210101__20210630_zHe9zlIWuNcf" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20200101__20200630_zxa11AjeCRt7" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 8pt Times New Roman, Times, Serif"> </td> <td colspan="7" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center">Three Months Ended</td><td style="font: bold 8pt Times New Roman, Times, Serif"> </td> <td colspan="7" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center">Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">June 30,</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">June 30,</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2020</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2021</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2020</td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Basic and Diluted LPS Computation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--NumeratorAbstract_i01B" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_i02_pp0p0_z2HEMxQqgenh" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 1pt">Loss available to common stockholders</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(1,718,903</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(1,146,010</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(3,098,173</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(2,997,095</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DenominatorAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font: 10pt Times New Roman, Times, Serif">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i01_pdd" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Weighted average number of common shares outstanding</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">102,075,557</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">87,751,941</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">101,177,844</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">86,211,828</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--EarningsPerShareBasicAndDiluted_i01_pdd" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Basic and diluted LPS</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.02</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.01</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.03</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.03</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

-1718903

-1146010

-3098173

-2997095

102075557

87751941

101177844

86211828

-0.02

-0.01

-0.03

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zYFEgYHisrj1" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Schedule of potentially dilutive securities) (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Schedule of potentially dilutive securities not included in the calculation of diluted net loss per share</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left">Series A Preferred stock (convertible)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zY7DzrAM0HCk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Preferred stock (convertible)">24,900,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zS7BiJWJssGb" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Preferred stock (convertible)">24,900,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Preferred stock (convertible)">24,900,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Preferred stock (convertible)">24,900,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Series B Preferred stock (convertible)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zRCPlawWWAhd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Preferred stock (convertible)">11,937,440</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zDosZJjTkEa6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Preferred stock (convertible)">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Preferred stock (convertible)">11,937,440</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Preferred stock (convertible)">—</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

24900000

11937440

Recoverability of Long-Lived Assets The Company assesses the recoverability of long-lived assets annually or whenever events or changes in circumstances indicate that expected future undiscounted cash flows might not be sufficient to support the carrying amount of an asset. The Company deems an asset to be impaired if a forecast of undiscounted future operating cash flows is less than the carrying amount. If an asset is determined to be impaired, the loss is measured as the amount by which the carrying value of the asset exceeds its fair value. There was no impairment of long-lived assets pertaining to the three and six month periods ended June 30, 2021 and 2020. However, there can be no assurances that future impairment tests will not result in a charge to operations.

Website and Development Costs Internal and external costs incurred to develop, the internal-use computer software during the application and development stage shall be capitalized subsequent to the preliminary project stage and when it is probable that the project will be completed. As of June 30, 2021, the Company has met the capitalization requirements and has incurred $452,244 in costs related to the development of the MediXall platform.

452244

Allowance for Uncollectible Accounts Receivable An allowance for uncollectible accounts receivable is recorded when management believes the uncollectability of the accounts receivable is confirmed. Subsequent recoveries, if any, are credited to the allowance. The allowance is determined based on management’s review of the debtor’s ability to repay and repayment history, aging history, and estimated value of collateral, if any.

Note 4 – Preferred Stock The Series A preferred shares are convertible into <span id="xdx_909_ecustom--ConvertiblePreferredStockTotalSharesIssuedUponConversion_c20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Number of common stock issuable for total shares of convertible preferred stock">24,900,000 common shares. The preferred shares do not pay dividends. The number of votes for the preferred shares shall be the same as the amount of shares of common shares that would be issued upon conversion. On June 24, 2020, the Company filed with the Secretary of State of the State of Nevada (the “Secretary of State”) a certificate of designation (the “Certificate of Designation”) of Series B Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”). The Certificate of Designation was effective upon filing with the Secretary of State and designated a new series of preferred stock of the Company as Series B Convertible Preferred Stock with <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20200624__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z5aVDXZU0y57" title="Convertible Preferred stock, shares authorized">4,000,000 shares authorized for issuance. Upon the occurrence of the events as set forth in paragraph (a) or (b) below, each share of Series B Preferred Stock shall be converted into four (the “Conversion Ratio”) fully paid and non-assessable shares of common stock or any shares of capital stock or other securities of the Company into which such common stock shall hereafter be changed or reclassified (the “Conversion Shares”) as set forth in the Certificate of Designation. (a) Automatic Conversion Immediately upon the listing of the common stock for trading on the New York Stock Exchange or the Nasdaq Stock Market, all of the issued and outstanding shares of Series B Preferred Stock shall automatically be converted into Conversion Shares without any further action of any holder of Series B Preferred Stock (each, a “Series B Holder” and collectively, “Series B Holders”). (b) Optional Conversion A Series B Holder shall have the right at any time during the period beginning on the date which is six months following the date that the Series B Preferred Stock is initially issued and prior to any automatic conversion as provided in the Certificate of Designation, to convert all or any part of the outstanding Series B Preferred Stock held by such Series B Holder into Conversion Shares at the Conversion Ratio as provided in the Certificate of Designation, subject to limitations set forth in the Certificate of Designation. Dividends Series B Holders will be entitled to receive a quarterly dividend, until the conversion of the Series B Preferred Stock, at the rate of 8% per annum (the “Series B Dividend”). The Series B Dividend will be cumulative, shall accrue quarterly, and be paid via the issuance of a number of shares of common stock of the Company equal to (1) the dollar amount of the Series B Dividend being paid, divided by (2) $0.25 (the “Stock Dividend”). The Stock Dividend shall be paid via the issuance to the applicable Series B Holder of the applicable shares of common stock via book entry in the books and records of the Company. At June 30, 2021, cumulative unpaid dividends on the Series B Preferred Stock amounted to $148,778. <span id="xdx_907_eus-gaap--CommonStockDividendsShares_do_c20210101__20210630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z4KjcTfZ5po3" title="Common stock issued in satisfaction of preferred stock dividend">No common stock has been issued as of June 30, 2021 in satisfaction of the preferred stock dividend. Voting Rights Each share of Series B Preferred Stock shall have a number of votes on any matter submitted to the holders of the Company’s common stock, or any class thereof, for a vote, equal to the number of Conversion Shares into which the Series B Preferred Stock is then convertible, and shall vote together with the common stock, or any class thereof, as applicable, as one class on such matter for as long as the share of Series B Preferred Stock is issued and outstanding.

24900000

0.001

4000000

0.08

0.25

148778

Note 5 – Related Party Transactions Pursuant to an agreement dated June 2013 and amended in June 2020, TBG Holdings Corp. (“TBG”), was engaged to provide business advisory services, manage and direct our public relations, provide recruiting services, develop and maintain material for market makers and investment bankers, provide general administrative services, and respond to incoming investor relations calls. TBG is owned in part by Neil Swartz, the Company’s Interim Chief Executive Officer and director, and a significant stockholder of the Company, and Timothy Hart, the Company’s Chief Financial Officer and director, and a significant stockholder of the Company. Under this agreement, we pay TBG a monthly fee of $40,000. In April 2021, we entered into an additional agreement with TBG to provide management services specifically to our Health Karma subsidiary. Under this new agreement, we pay TBG an additional monthly fee of $40,000. During the three months ended June 30, 2021 and 2020, the Company expensed $240,000 and $120,000, respectively, of related party management fees related to these agreements. During the six months ended June 30, 2021 and 2020, the Company expensed $360,000 and $240,000, respectively, of related party management fees related to these agreements. At June 30, 2021 and December 31, 2020, the Company had prepaid management fees related to the aforementioned agreement with TBG amounting to $465,000 and $480,000, respectively. R3 Accounting LLC (“R3”), owned by Mr. Hart, provides accounting, tax and bookkeeping services to the Company. During the three and six months ended June 30, 2021 and 2020, the Company expensed $<span id="xdx_90E_eus-gaap--RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_pp0p0_c20210401__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--R3AccountingLLCMember_zHNZcAMtarb4">65,500 and $<span id="xdx_90F_eus-gaap--RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_pp0p0_c20200401__20200630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--R3AccountingLLCMember_zIFR7V0lwpze">103,500 and $135,538 and $141,000, respectively, related to R3 services. At June 30, 2021 and December 31, 2020, the Company had short term cash advances outstanding due to Turnkey Capital, Inc. (“Turnkey”), a related party of the Company. The advances are due on demand, are unsecured, and do not bear any interest. During the three and six month period ended June 30, 2021, the Company paid $181,500 and $275,500 in marketing and consulting expenses to two companies which are owned by the president of Turnkey a related party. There was no such fee during the three and six month period ended June 30, 2020. Prepaid expenses (accounts payable and accrued expenses) to related parties are as follows: <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zJIx7ZxGbCAa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Related Party Transactions (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Schedule of prepaid expenses (accounts payable and accrued expenses) to related parties</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: justify">Related Party</td><td style="font-size: 8pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center">At June 30, 2021</td><td style="font-size: 8pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center">At December 31, 2020</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 66%; font-size: 10pt; text-align: justify">TBG</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_eus-gaap--PrepaidExpenseCurrent_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TBGHoldingsCorpMember_pp0p0" style="width: 14%; font-size: 10pt; text-align: right" title="Prepaid expenses- related party">465,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_985_eus-gaap--PrepaidExpenseCurrent_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TBGHoldingsCorpMember_pp0p0" style="width: 14%; font-size: 10pt; text-align: right" title="Prepaid expenses- related party">480,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Turnkey</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--AccountsPayableRelatedPartiesCurrent_iNI_pp0p0_di_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TurnkeyMember_zFOzuf7wDJ4g" style="font-size: 10pt; text-align: right" title="Accounts payable and accrued expenses - related party">(457,300</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_989_eus-gaap--AccountsPayableRelatedPartiesCurrent_iNI_pp0p0_di_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TurnkeyMember_zFgvLGTlddvi" style="font-size: 10pt; text-align: right" title="Accounts payable and accrued expenses - related party">(457,300</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">R3</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_989_eus-gaap--AccountsPayableRelatedPartiesCurrent_iNI_pp0p0_di_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--R3AccountingLLCMember_zsTeDECbxjHk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accounts payable and accrued expenses - related party">(19,931</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--AccountsPayableRelatedPartiesCurrent_iNI_pp0p0_di_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--R3AccountingLLCMember_zkyEt8dlfXNl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accounts payable and accrued expenses - related party">(19,931</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_981_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Due from (to) related party">(12,231</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Due from (to) related party">2,769</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> EGG Agreement On September 13, 2019, Turnkey entered into a Definitive Acquisition Agreement with Healthspan Medical Systems, Inc., doing business as EGG Health Hub, Inc. (“EGG”). On October 29, 2020, Turnkey and EGG executed a share exchange agreement in which EGG became a wholly owned subsidiary of Turnkey. Turnkey and EGG are related parties of the Company. EGG does not currently conduct any operations. EGG is a brand new model for healthcare and wellness that brings together top physicians and wellness professionals into co-practicing communities with shared access to a full-stack technology platform – scheduling, billing, client acquisition, and telemedicine – and flexible access to office space designed to optimize both the physician and client experience. This model creates a compelling new option for re-tenanting traditional shopping centers and mixed-use space. On July 27, 2020, the Company and Turnkey entered into an agreement in which the Company issued 1,000,000 shares of its common stock to Turnkey in exchange for the exclusive technology rights to develop EGG’s business model (as described in the preceding paragraph) with the Company’s technological infrastructure, including but not limited to the use of the Company’s healthcare website platform. The transaction was accounted for at historical cost as a transaction under common ownership that lacks commercial substance. As such, the issuance of the Company’s common stock to Turnkey was recorded as an increase of $1,000 to common stock, with a corresponding decrease to additional paid-in capital.

40000

240000 120000 360000 240000

465000

480000

65500

103500

135538

141000

181500

275500

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zJIx7ZxGbCAa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Related Party Transactions (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Schedule of prepaid expenses (accounts payable and accrued expenses) to related parties</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: justify">Related Party</td><td style="font-size: 8pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center">At June 30, 2021</td><td style="font-size: 8pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: center">At December 31, 2020</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="width: 66%; font-size: 10pt; text-align: justify">TBG</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_989_eus-gaap--PrepaidExpenseCurrent_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TBGHoldingsCorpMember_pp0p0" style="width: 14%; font-size: 10pt; text-align: right" title="Prepaid expenses- related party">465,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_985_eus-gaap--PrepaidExpenseCurrent_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TBGHoldingsCorpMember_pp0p0" style="width: 14%; font-size: 10pt; text-align: right" title="Prepaid expenses- related party">480,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Turnkey</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--AccountsPayableRelatedPartiesCurrent_iNI_pp0p0_di_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TurnkeyMember_zFOzuf7wDJ4g" style="font-size: 10pt; text-align: right" title="Accounts payable and accrued expenses - related party">(457,300</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_989_eus-gaap--AccountsPayableRelatedPartiesCurrent_iNI_pp0p0_di_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TurnkeyMember_zFgvLGTlddvi" style="font-size: 10pt; text-align: right" title="Accounts payable and accrued expenses - related party">(457,300</td><td style="font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,204)"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">R3</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_989_eus-gaap--AccountsPayableRelatedPartiesCurrent_iNI_pp0p0_di_c20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--R3AccountingLLCMember_zsTeDECbxjHk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accounts payable and accrued expenses - related party">(19,931</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_986_eus-gaap--AccountsPayableRelatedPartiesCurrent_iNI_pp0p0_di_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--R3AccountingLLCMember_zkyEt8dlfXNl" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Accounts payable and accrued expenses - related party">(19,931</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_981_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Due from (to) related party">(12,231</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Due from (to) related party">2,769</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table>

465000

480000

457300

19931

-12231

2769

1000000 1000

Note 6 – Long Term Debt During May 2020, the Company received a Paycheck Protection Program loan in the amount of $165,719. The Small Business Administration forgave the full amount of the loan in June 2021. Accordingly, the Company has derecognized the loan and recognized the revenue of $165,719 from loan forgiveness.

165719

165719 -165719

Note 7 – Legal Contingencies The Company has received a Subpoena from the SEC requesting certain documents in connection with an investigation styled, “In the Matter of TBG Holdings Corporation”. This investigation is a non-public, fact-finding inquiry and does not require disclosure by the Company. The Company has decided to disclose this matter in order to more fully keep our shareholders apprised of matters affecting the Company and its shareholders. The investigation in no way has made a conclusion that anyone has violated any securities laws or regulations. Also, this investigation does not mean the SEC has a negative opinion of any person, entity, or security. All SEC investigations are conducted privately. TBG Holdings Corp. (“TBG”) is owned in part by Neil Swartz, the Company’s Interim Chief Executive Officer and Chairman of the Board, and a significant stockholder of the Company, and Timothy Hart, the Company’s Chief Financial Officer, Treasurer, Secretary and director, and a significant stockholder of the Company. Pursuant to an agreement dated June 2013 and amended on May 20, 2019, TBG was engaged to provide business advisory services, manage and direct our public relations, provide recruiting services, develop and maintain material for market makers and investment bankers, provide general administrative services, and respond to incoming investor relations calls. In April, 2021 the Company entered into an additional contract with TBG to provide management services to our wholly-owned subsidiary, Health Karma, Inc. Under these agreements, the Company pays TBG a monthly fee of $80,000. As part of its investigation, the SEC has requested certain financial documents and information related to the Company, as well as documents related to transactions with R3 Accounting LLC (“R3”) and other entities. R3, owned by Mr. Hart, provides accounting, tax, and bookkeeping services to the Company. As part of its investigation, the SEC has requested certain financial documents and information related to the Company, as well as documents related to transactions with R3, TBG and other entities. All transactions between the Company and each of TBG and R3 are routinely updated and disclosed in the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, each as filed with the SEC. These filings can be found on the SEC’s public web site at https://www.sec.gov/cgi-bin/browse-edgar?CIK=1601280&owner=exclude. The web site is not incorporated herein by reference and is not a part of this Quarterly Report on Form 10-Q. The Company is cooperating fully with the SEC in its investigation and has supplied, and if requested, will continue to supply, the SEC with all documents requested in a timely fashion. To date, the SEC has not informed the Company that it has opened an investigation into the Company and at this time, the Company is not aware of any investigation into the Company by the SEC. From time to time, the Company may be the subject of pending or threatened legal actions and proceedings, including those that arise in the ordinary course of business. Management is not aware of any material pending legal proceedings, other than ordinary routine litigation incidental to the business, or proceedings known to be contemplated by governmental authorities, to which the Company or any of its subsidiaries is a party or of which any of their property is the subject. As of the date of this Quarterly Report on Form 10-Q, there are no material proceedings to which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or any associate of any such director, officer, affiliate of the Company, or security holder is a party adverse to the Company or any of its subsidiaries or has a material interest adverse to the Company or any of its subsidiaries.

80000

XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2021	Sep. 30, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	333-194337
Entity Registrant Name	MediXall Group, Inc.
Entity Central Index Key	0001601280
Entity Tax Identification Number	33-0864127
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	2929 East Commercial Blvd.
Entity Address, Address Line Two	PH-D
Entity Address, City or Town	Ft. Lauderdale
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33308
City Area Code	954
Local Phone Number	440-4678
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		106,148,845

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash	$ 125,354	$ 645,762
Prepaid expenses - related party	465,000	480,000
Other assets		8,000
Total current assets	590,354	1,133,762
Furniture and equipment, net	23,696	26,536
Right-of-use-operating lease asset	7,003	43,757
Website and development costs	452,244	439,404
Total assets	1,073,297	1,643,459
CURRENT LIABILITIES:
Accounts payable and accrued expenses	224,436	571,405
Accounts payable and accrued expenses - related party	477,231	477,231
Operating lease liability	8,493	47,200
Note payable		25,373
Total current liabilities	710,160	1,121,209
Note payable, net of current portion		140,346
Total liabilities	710,160	1,261,555
STOCKHOLDERS' EQUITY:
Common Stock, $0.001 par value 750,000,000 shares authorized; 105,389,180 and 98,898,130 shares issued and outstanding	105,389	98,898
Additional paid-in capital	22,827,832	19,862,918
Accumulated deficit	(22,573,333)	(19,581,816)
Total stockholders' equity	363,137	381,904
Total liabilities and stockholders' equity	1,073,297	1,643,459
Series A Preferred Stock [Member]
STOCKHOLDERS' EQUITY:
Preferred Stock, Value, Issued	265	265
Series B Preferred Stock [Member]
STOCKHOLDERS' EQUITY:
Preferred Stock, Value, Issued	$ 2,984	$ 1,639

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Common Stock, Par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, shares authorized	750,000,000	750,000,000
Common Stock, shares issued	105,389,180	98,898,130
Common Stock, shares outstanding	105,389,180	98,898,130
Series A Preferred Stock [Member]
Convertible Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Convertible Preferred stock, shares authorized	1,000,000	1,000,000
Convertible Preferred stock, shares issued	264,894	264,894
Convertible Preferred stock, shares outstanding	264,894	264,894
Series B Preferred Stock [Member]
Convertible Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Convertible Preferred stock, shares authorized	4,000,000	4,000,000
Convertible Preferred stock, shares issued	2,984,360	1,639,360
Convertible Preferred stock, shares outstanding	2,984,360	1,639,360

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenue	$ 166,642		$ 169,913
Operating Expenses
Professional fees	342,080	257,177	681,660	904,441
Professional fees - related party	247,000	103,500	411,038	141,000
Management fees - related party	240,000	120,000	360,000	240,000
Personnel related expenses	682,361	608,337	1,283,911	1,569,827
Other selling, general and administrative	314,417	56,996	424,821	141,827
Total Operating Expenses	1,825,858	1,146,010	3,161,430	2,997,095
Loss before income taxes	(1,659,216)	(1,146,010)	(2,991,517)	(2,997,095)
Income taxes
Net loss	(1,659,216)	(1,146,010)	(2,991,517)	(2,997,095)
Less preferred stock dividends	59,687		106,656
Net loss to common shareholders	$ (1,718,903)	$ (1,146,010)	$ (3,098,173)	$ (2,997,095)
Net loss per common share - basic and diluted	$ (0.02)	$ (0.01)	$ (0.03)	$ (0.03)
Weighted average number of common shares outstanding during the periods - basic and diluted	102,075,557	87,751,941	101,177,844	86,211,828

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Series A Voting Preferred Stock [Member]	Series B Voting Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 265		$ 80,953	$ 13,966,326	$ (13,649,784)	$ 397,760
Beginning balance shares at Dec. 31, 2019	264,894		80,952,554
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs (unaudited)			$ 1,907	499,843		501,750
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs (unaudited), Shares			1,907,000
Common stock issued for services (unaudited)			$ 3,964	1,039,101		1,043,065
Common stock issued for services (unaudited), Shares			3,964,376
Net loss (unaudited)					(1,851,085)	(1,851,085)
Ending balance, value at Mar. 31, 2020	$ 265		$ 86,824	15,505,270	(15,500,869)	91,490
Ending balance shares at Mar. 31, 2020	264,894		86,823,930
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs (unaudited)			$ 2,350	594,650		597,000
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs (unaudited), Shares			2,350,000
Proceeds received from sale of Preferred Stock (unaudited)		$ 500		499,500		500,000
Proceeds received from sale of Preferred Stock,shares		500,000
Common stock issued for services (unaudited)			$ 1,880	468,120		470,000
Common stock issued for services (unaudited), Shares			1,880,000
Net loss (unaudited)					(1,146,010)	(1,146,010)
Ending balance, value at Jun. 30, 2020	$ 265	$ 500	$ 91,054	17,067,540	(16,646,879)	512,480
Ending balance shares at Jun. 30, 2020	264,894	500,000	91,053,930
Beginning balance, value at Dec. 31, 2020	$ 265	$ 1,639	$ 98,898	19,862,918	(19,581,816)	381,904
Beginning balance shares at Dec. 31, 2020	264,894	1,639,360	98,898,130
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs (unaudited)			$ 2,488	619,387		621,875
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs (unaudited), Shares			2,487,550
Proceeds received from sale of Preferred Stock (unaudited)		$ 1,345		1,343,655		1,345,000
Proceeds received from sale of Preferred Stock (unaudited), Shares		1,345,000
Net loss (unaudited)					(1,332,301)	(1,332,301)
Ending balance, value at Mar. 31, 2021	$ 265	$ 2,984	$ 101,386	21,825,960	(20,914,117)	1,016,478
Ending balance shares at Mar. 31, 2021	264,894	2,984,360	101,385,680
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs (unaudited)			$ 1,289	326,211		327,500
Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs (unaudited), Shares			1,290,000
Common stock issued for services (unaudited)			$ 2,714	675,661		678,375
Common stock issued for services (unaudited), Shares			2,713,500
Net loss (unaudited)					(1,659,216)	(1,659,216)
Ending balance, value at Jun. 30, 2021	$ 265	$ 2,984	$ 105,389	$ 22,827,832	$ (22,573,333)	$ 363,137
Ending balance shares at Jun. 30, 2021	264,894	2,984,360	105,389,180

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - USD ($)	3 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020
Common Stock [Member]
Offering costs	$ 0	$ 0	$ 3,000	$ 0

XML 18 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,991,517)	$ (2,997,095)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	2,840	2,000
Common stock issued as compensation for services	678,375	1,513,065
Gain from forgiveness of note payable	(165,719)
Changes in operating assets and liabilities:
Prepaid expenses- related party	15,000	(45,430)
Other assets	8,000
Accounts payable and accrued expenses	(346,969)	157,720
Accounts payable and accrued expenses - related party		(241,870)
Amortization of right-of-use operating lease asset	36,754	34,302
Operating lease liability	(38,707)	(33,926)
Net cash used in operating activities	(2,801,943)	(1,611,234)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of furniture and equipment		(12,429)
Website development costs	(12,840)	(14,600)
Net cash used in investing activities	(12,840)	(27,029)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the sale of common stock, net of offering costs	949,375	1,098,750
Proceeds from the sale of preferred stock	1,345,000	500,000
Proceeds from note payable		165,720
Net cash provided by financing activities	2,294,375	1,764,470
Net (decrease) increase in cash	(520,408)	126,207
Cash at beginning of period	645,762	446,219
Cash at end of period	125,354	572,426
Supplemental disclosures of non-cash information
Decrease in note payable resulting from gain on forgiveness of note payable	$ (165,719)

XML 19 R8.htm IDEA: XBRL DOCUMENT

Organization and Nature of Operation

6 Months Ended

Jun. 30, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Nature of Operation

Note 1 - Organization and Nature of Operation

XML 20 R9.htm IDEA: XBRL DOCUMENT

Going Concern

6 Months Ended

Jun. 30, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Going Concern

Note 2 – Going Concern

XML 21 R10.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 3 - Summary of Significant Accounting Policies

Basis of Presentation

Principles of Consolidation

Use of Estimates

Subsequent Events

Risks and Uncertainties

Income Taxes

Revenue Recognition

Share-Based Payment Arrangements

Loss Per Share

Following is the computation of basic and diluted loss per share for the three and month periods ended June 30, 2021 and 2020:

Three Months Ended Six Months Ended

June 30, June 30,

2021 2020 2021 2020

Basic and Diluted LPS Computation

Numerator:

Loss available to common stockholders $ (1,718,903 ) $ (1,146,010 ) $ (3,098,173 ) $ (2,997,095 )

Denominator:

Weighted average number of common shares outstanding 102,075,557 87,751,941 101,177,844 86,211,828

Basic and diluted LPS $ (0.02 ) $ (0.01 ) $ (0.03 ) $ (0.03 )



Series A Preferred stock (convertible)	24,900,000	24,900,000	24,900,000	24,900,000
Series B Preferred stock (convertible)	11,937,440	—	11,937,440	—

Recoverability of Long-Lived Assets

Website and Development Costs

Allowance for Uncollectible Accounts Receivable

XML 22 R11.htm IDEA: XBRL DOCUMENT

Preferred Stock

6 Months Ended

Jun. 30, 2021

Equity [Abstract]

Preferred Stock

Note 4 – Preferred Stock

(a) Automatic Conversion

Immediately upon the listing of the common stock for trading on the New York Stock Exchange or the Nasdaq Stock Market, all of the issued and outstanding shares of Series B Preferred Stock shall automatically be converted into Conversion Shares without any further action of any holder of Series B Preferred Stock (each, a “Series B Holder” and collectively, “Series B Holders”).

(b) Optional Conversion

A Series B Holder shall have the right at any time during the period beginning on the date which is six months following the date that the Series B Preferred Stock is initially issued and prior to any automatic conversion as provided in the Certificate of Designation, to convert all or any part of the outstanding Series B Preferred Stock held by such Series B Holder into Conversion Shares at the Conversion Ratio as provided in the Certificate of Designation, subject to limitations set forth in the Certificate of Designation.

Dividends

Series B Holders will be entitled to receive a quarterly dividend, until the conversion of the Series B Preferred Stock, at the rate of 8% per annum (the “Series B Dividend”). The Series B Dividend will be cumulative, shall accrue quarterly, and be paid via the issuance of a number of shares of common stock of the Company equal to (1) the dollar amount of the Series B Dividend being paid, divided by (2) $0.25 (the “Stock Dividend”). The Stock Dividend shall be paid via the issuance to the applicable Series B Holder of the applicable shares of common stock via book entry in the books and records of the Company. At June 30, 2021, cumulative unpaid dividends on the Series B Preferred Stock amounted to $148,778. No common stock has been issued as of June 30, 2021 in satisfaction of the preferred stock dividend.

Voting Rights

Each share of Series B Preferred Stock shall have a number of votes on any matter submitted to the holders of the Company’s common stock, or any class thereof, for a vote, equal to the number of Conversion Shares into which the Series B Preferred Stock is then convertible, and shall vote together with the common stock, or any class thereof, as applicable, as one class on such matter for as long as the share of Series B Preferred Stock is issued and outstanding.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Jun. 30, 2021

Related Party Transactions

Note 5 – Related Party Transactions

At June 30, 2021 and December 31, 2020, the Company had prepaid management fees related to the aforementioned agreement with TBG amounting to $465,000 and $480,000, respectively.

Prepaid expenses (accounts payable and accrued expenses) to related parties are as follows:


Related Party	At June 30, 2021			At December 31, 2020
TBG	$	465,000		$	480,000
Turnkey		(457,300	)		(457,300	)
R3		(19,931	)		(19,931	)
	$	(12,231	)	$	2,769

EGG Agreement

XML 24 R13.htm IDEA: XBRL DOCUMENT

Long Term Debt

6 Months Ended

Jun. 30, 2021

Debt Disclosure [Abstract]

Long Term Debt

Note 6 – Long Term Debt

XML 25 R14.htm IDEA: XBRL DOCUMENT

Legal Contingencies

6 Months Ended

Jun. 30, 2021

Commitments and Contingencies Disclosure [Abstract]

Legal Contingencies

Note 7 – Legal Contingencies

As part of its investigation, the SEC has requested certain financial documents and information related to the Company, as well as documents related to transactions with R3, TBG and other entities.

The Company is cooperating fully with the SEC in its investigation and has supplied, and if requested, will continue to supply, the SEC with all documents requested in a timely fashion.

To date, the SEC has not informed the Company that it has opened an investigation into the Company and at this time, the Company is not aware of any investigation into the Company by the SEC.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Principles of Consolidation

Principles of Consolidation

Use of Estimates

Use of Estimates

Subsequent Events

Subsequent Events

Risks and Uncertainties

Risks and Uncertainties

Income Taxes

Income Taxes

Revenue Recognition

Revenue Recognition

Share-Based Payment Arrangements

Share-Based Payment Arrangements

Loss Per Share

Loss Per Share

Following is the computation of basic and diluted loss per share for the three and month periods ended June 30, 2021 and 2020:



Series A Preferred stock (convertible)	24,900,000	24,900,000	24,900,000	24,900,000
Series B Preferred stock (convertible)	11,937,440	—	11,937,440	—

Recoverability of Long-Lived Assets

Recoverability of Long-Lived Assets

Website and Development Costs

Website and Development Costs

Allowance for Uncollectible Accounts Receivable

Allowance for Uncollectible Accounts Receivable

XML 27 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Schedule of computation of basic and diluted net loss per share



	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2021			2020			2021			2020
Basic and Diluted LPS Computation
Numerator:
Loss available to common stockholders	$	(1,718,903	)	$	(1,146,010	)	$	(3,098,173	)	$	(2,997,095	)

Denominator:
Weighted average number of common shares outstanding		102,075,557			87,751,941			101,177,844			86,211,828

Basic and diluted LPS	$	(0.02	)	$	(0.01	)	$	(0.03	)	$	(0.03	)

Schedule of potentially dilutive securities not included in the calculation of diluted net loss per share



Series A Preferred stock (convertible)	24,900,000	24,900,000	24,900,000	24,900,000
Series B Preferred stock (convertible)	11,937,440	—	11,937,440	—

XML 28 R17.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Tables)

6 Months Ended

Jun. 30, 2021

Schedule of prepaid expenses (accounts payable and accrued expenses) to related parties


Related Party	At June 30, 2021			At December 31, 2020
TBG	$	465,000		$	480,000
Turnkey		(457,300	)		(457,300	)
R3		(19,931	)		(19,931	)
	$	(12,231	)	$	2,769

XML 29 R18.htm IDEA: XBRL DOCUMENT

Going Concern (Details Narrative) - USD ($)	6 Months Ended
Going Concern (Details Narrative) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Accumulated deficit	$ 22,573,333	$ 19,581,816
Common Stock [Member]
Stock issued	1,499,040
Proceeds from issue of stock	$ 404,666
Preferred Stock [Member]
Stock issued	665,000
Proceeds from issue of stock	$ 665,000

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References + Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Schedule of Basic and Diluted EPS) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Numerator:
Loss available to common stockholders	$ (1,718,903)	$ (1,146,010)	$ (3,098,173)	$ (2,997,095)
Denominator:
Weighted average number of common shares outstanding	102,075,557	87,751,941	101,177,844	86,211,828
Basic and diluted LPS	$ (0.02)	$ (0.01)	$ (0.03)	$ (0.03)

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.

+ References + Details

XML 31 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Schedule of potentially dilutive securities) (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Series A Preferred Stock [Member]
Preferred stock (convertible)	24,900,000	24,900,000	24,900,000	24,900,000
Series B Preferred Stock [Member]
Preferred stock (convertible)	11,937,440		11,937,440

XML 32 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative)	Jun. 30, 2021 USD ($)
Accounting Policies [Abstract]
Website and development costs	$ 452,244

XML 33 R22.htm IDEA: XBRL DOCUMENT

Preferred Stock (Details Narrative) - USD ($)	6 Months Ended
Preferred Stock (Details Narrative) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Jun. 24, 2020
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Number of common stock issuable for total shares of convertible preferred stock	24,900,000
Convertible Preferred stock, par value	$ 0.001	$ 0.001
Convertible Preferred stock, shares authorized	1,000,000	1,000,000
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Convertible Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Convertible Preferred stock, shares authorized	4,000,000	4,000,000	4,000,000
Dividend rate	8.00%
Stock dividend	$ 0.25
Cummulative unpaid dividends	$ 148,778
Common stock issued in satisfaction of preferred stock dividend	0

XML 34 R23.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Prepaid expenses- related party	$ 465,000	$ 480,000
Accounts payable and accrued expenses - related party	(477,231)	(477,231)
Due from (to) related party	(12,231)	2,769
T B G Holdings Corp [Member]
Related Party Transaction [Line Items]
Prepaid expenses- related party	465,000	480,000
Turnkey [Member]
Related Party Transaction [Line Items]
Accounts payable and accrued expenses - related party	(457,300)	(457,300)
R3 Accounting LLC [Member]
Related Party Transaction [Line Items]
Accounts payable and accrued expenses - related party	$ (19,931)	$ (19,931)

- Definition

Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

+ Details

XML 35 R24.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
	Apr. 30, 2021	Jul. 27, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Related Party Transaction [Line Items]
Debt Instrument, Periodic Payment	$ 40,000
Management Fee Related Party			$ 240,000	$ 120,000	$ 360,000	$ 240,000
Marketing and Consulting expenses			181,500	0	275,500	0
T B G [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party					40,000
Management Fee Related Party			240,000	120,000
Prepaid expenses- related party			465,000		465,000		$ 480,000
R3 Accounting LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party			$ 65,500	$ 103,500	135,538	$ 141,000
Turnkey [Member]
Related Party Transaction [Line Items]
Number of shares exchanged		1,000,000
Common stock issued to related party					$ 1,000

XML 36 R25.htm IDEA: XBRL DOCUMENT

Long Term Debt (Details Narrative) - USD ($)	1 Months Ended		6 Months Ended
Long Term Debt (Details Narrative) - USD ($)	Jun. 30, 2021	May 31, 2021	Jun. 30, 2021	Jun. 30, 2020
Debt Disclosure [Abstract]
PPP loan		$ 165,719
PPP Loan forgave	$ 165,719
Gain from forgiveness of note payable			$ 165,719

XML 37 R26.htm IDEA: XBRL DOCUMENT

Legal Contingencies (Details Narrative)	6 Months Ended
Legal Contingencies (Details Narrative)	Jun. 30, 2021 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Monthly fee	$ 80,000

EXCEL 38 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

XML 39 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 40 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 98 211 1 false 12 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://medixall.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://medixall.com/role/CondendsedConsolidatedBalanceSheets CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://medixall.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Organization and Nature of Operation Sheet http://medixall.com/role/OrganizationAndNatureOfOperation Organization and Nature of Operation Notes 8 false false R9.htm 00000009 - Disclosure - Going Concern Sheet http://medixall.com/role/GoingConcern Going Concern Notes 9 false false R10.htm 00000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://medixall.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 00000011 - Disclosure - Preferred Stock Sheet http://medixall.com/role/PreferredStock Preferred Stock Notes 11 false false R12.htm 00000012 - Disclosure - Related Party Transactions Sheet http://medixall.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 00000013 - Disclosure - Long Term Debt Sheet http://medixall.com/role/LongTermDebt Long Term Debt Notes 13 false false R14.htm 00000014 - Disclosure - Legal Contingencies Sheet http://medixall.com/role/LegalContingencies Legal Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://medixall.com/role/SummaryOfSignificantAccountingPolicies 15 false false R16.htm 00000016 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://medixall.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://medixall.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Related Party Transactions (Tables) Sheet http://medixall.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://medixall.com/role/RelatedPartyTransactions 17 false false R18.htm 00000018 - Disclosure - Going Concern (Details Narrative) Sheet http://medixall.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://medixall.com/role/GoingConcern 18 false false R19.htm 00000019 - Disclosure - Summary of Significant Accounting Policies (Schedule of Basic and Diluted EPS) (Details) Sheet http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedEpsDetails Summary of Significant Accounting Policies (Schedule of Basic and Diluted EPS) (Details) Details http://medixall.com/role/SummaryOfSignificantAccountingPoliciesTables 19 false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies (Schedule of potentially dilutive securities) (Details) Sheet http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails Summary of Significant Accounting Policies (Schedule of potentially dilutive securities) (Details) Details http://medixall.com/role/SummaryOfSignificantAccountingPoliciesTables 20 false false R21.htm 00000021 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://medixall.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://medixall.com/role/SummaryOfSignificantAccountingPoliciesTables 21 false false R22.htm 00000022 - Disclosure - Preferred Stock (Details Narrative) Sheet http://medixall.com/role/PreferredStockDetailsNarrative Preferred Stock (Details Narrative) Details http://medixall.com/role/PreferredStock 22 false false R23.htm 00000023 - Disclosure - Related Party Transactions (Details) Sheet http://medixall.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://medixall.com/role/RelatedPartyTransactionsTables 23 false false R24.htm 00000024 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://medixall.com/role/RelatedPartyTransactionsTables 24 false false R25.htm 00000025 - Disclosure - Long Term Debt (Details Narrative) Sheet http://medixall.com/role/LongTermDebtDetailsNarrative Long Term Debt (Details Narrative) Details http://medixall.com/role/LongTermDebt 25 false false R26.htm 00000026 - Disclosure - Legal Contingencies (Details Narrative) Sheet http://medixall.com/role/LegalContingenciesDetailsNarrative Legal Contingencies (Details Narrative) Details http://medixall.com/role/LegalContingencies 26 false false All Reports Book All Reports mdxl_10q-063021.htm mdxl-20210630.xsd mdxl-20210630_cal.xml mdxl-20210630_def.xml mdxl-20210630_lab.xml mdxl-20210630_pre.xml mdxl_ex31z1.htm mdxl_ex31z2.htm mdxl_ex32z1.htm mdxl_ex32z2.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 true true JSON 43 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mdxl_10q-063021.htm": { "axisCustom": 0, "axisStandard": 3, "contextCount": 98, "dts": { "calculationLink": { "local": [ "mdxl-20210630_cal.xml" ] }, "definitionLink": { "local": [ "mdxl-20210630_def.xml" ] }, "inline": { "local": [ "mdxl_10q-063021.htm" ] }, "labelLink": { "local": [ "mdxl-20210630_lab.xml" ] }, "presentationLink": { "local": [ "mdxl-20210630_pre.xml" ] }, "schema": { "local": [ "mdxl-20210630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 223, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 55, "http://medixall.com/20210630": 6, "http://xbrl.sec.gov/dei/2021": 5, "total": 66 }, "keyCustom": 12, "keyStandard": 199, "memberCustom": 6, "memberStandard": 6, "nsprefix": "mdxl", "nsuri": "http://medixall.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://medixall.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Summary of Significant Accounting Policies", "role": "http://medixall.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Preferred Stock", "role": "http://medixall.com/role/PreferredStock", "shortName": "Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Related Party Transactions", "role": "http://medixall.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Long Term Debt", "role": "http://medixall.com/role/LongTermDebt", "shortName": "Long Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Legal Contingencies", "role": "http://medixall.com/role/LegalContingencies", "shortName": "Legal Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Related Party Transactions (Tables)", "role": "http://medixall.com/role/RelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Going Concern (Details Narrative)", "role": "http://medixall.com/role/GoingConcernDetailsNarrative", "shortName": "Going Concern (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-012021-06-30_us-gaap_CommonStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Summary of Significant Accounting Policies (Schedule of Basic and Diluted EPS) (Details)", "role": "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedEpsDetails", "shortName": "Summary of Significant Accounting Policies (Schedule of Basic and Diluted EPS) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "role": "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "shortName": "CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "lang": null, "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-04-012021-06-30_us-gaap_SeriesAPreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Summary of Significant Accounting Policies (Schedule of potentially dilutive securities) (Details)", "role": "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails", "shortName": "Summary of Significant Accounting Policies (Schedule of potentially dilutive securities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-04-012021-06-30_us-gaap_SeriesAPreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CapitalizedComputerSoftwareNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "role": "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CapitalizedComputerSoftwareNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PreferredStockTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "AsOf2021-06-30_us-gaap_SeriesAPreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "mdxl:ConvertiblePreferredStockTotalSharesIssuedUponConversion", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Preferred Stock (Details Narrative)", "role": "http://medixall.com/role/PreferredStockDetailsNarrative", "shortName": "Preferred Stock (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PreferredStockTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "AsOf2021-06-30_us-gaap_SeriesAPreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "mdxl:ConvertiblePreferredStockTotalSharesIssuedUponConversion", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Related Party Transactions (Details)", "role": "http://medixall.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "lang": null, "name": "us-gaap:RelatedPartyTransactionDueFromToRelatedParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-04-012021-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentPeriodicPayment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Related Party Transactions (Details Narrative)", "role": "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-04-012021-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentPeriodicPayment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-05-012021-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Long Term Debt (Details Narrative)", "role": "http://medixall.com/role/LongTermDebtDetailsNarrative", "shortName": "Long Term Debt (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-05-012021-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:LegalMattersAndContingenciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LegalFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Legal Contingencies (Details Narrative)", "role": "http://medixall.com/role/LegalContingenciesDetailsNarrative", "shortName": "Legal Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:LegalMattersAndContingenciesTextBlock", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LegalFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "role": "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENDSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "role": "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-04-012021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "AsOf2019-12-31_custom_SeriesAVotingPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "role": "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "AsOf2019-12-31_custom_SeriesAVotingPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-04-012021-06-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)", "role": "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-04-012021-06-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "role": "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": "0", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Organization and Nature of Operation", "role": "http://medixall.com/role/OrganizationAndNatureOfOperation", "shortName": "Organization and Nature of Operation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Going Concern", "role": "http://medixall.com/role/GoingConcern", "shortName": "Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mdxl_10q-063021.htm", "contextRef": "From2021-01-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 12, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r269", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://medixall.com/role/Cover" ], "xbrltype": "booleanItemType" }, "mdxl_CommonStockIssuedToRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued to related party.", "label": "Common stock issued to related party" } } }, "localname": "CommonStockIssuedToRelatedParty", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mdxl_ConvertiblePreferredStockTotalSharesIssuedUponConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for total shares of convertible preferred stock that is converted.", "label": "Number of common stock issuable for total shares of convertible preferred stock" } } }, "localname": "ConvertiblePreferredStockTotalSharesIssuedUponConversion", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "mdxl_DenominatorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominator:" } } }, "localname": "DenominatorAbstract", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedEpsDetails" ], "xbrltype": "stringItemType" }, "mdxl_GainFromForgivenessOfNotePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Decrease in note payable resulting from gain on forgiveness of note payable", "negatedLabel": "Gain from forgiveness of note payable" } } }, "localname": "GainFromForgivenessOfNotePayable", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://medixall.com/role/LongTermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mdxl_GainFromForgivenessOfNotePayable1": { "auth_ref": [], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "GainFromForgivenessOfNotePayable1", "negatedLabel": "Gain from forgiveness of note payable" } } }, "localname": "GainFromForgivenessOfNotePayable1", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mdxl_ManagementFeeRelatedParty": { "auth_ref": [], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Management fees - related party", "verboseLabel": "Management Fee Related Party" } } }, "localname": "ManagementFeeRelatedParty", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations", "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mdxl_NumberOfSharesExchanged": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares exchanged.", "label": "Number of shares exchanged" } } }, "localname": "NumberOfSharesExchanged", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "mdxl_NumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator:" } } }, "localname": "NumeratorAbstract", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedEpsDetails" ], "xbrltype": "stringItemType" }, "mdxl_PppLoanForgave": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "PPP Loan forgave" } } }, "localname": "PppLoanForgave", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/LongTermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "mdxl_ProceedsFromLongTermDebt": { "auth_ref": [], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from note payable" } } }, "localname": "ProceedsFromLongTermDebt", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mdxl_ProceedsReceivedFromSaleOfPreferredStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of preferred stock sold during the period.", "label": "Proceeds received from sale of Preferred Stock (unaudited), Shares" } } }, "localname": "ProceedsReceivedFromSaleOfPreferredStockShares", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "mdxl_ProceedsReceivedFromSaleOfPreferredStockValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Proceeds received from sale of Preferred Stock (unaudited)" } } }, "localname": "ProceedsReceivedFromSaleOfPreferredStockValue", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "mdxl_ProfessionalFeesRelatedParty": { "auth_ref": [], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Professional fees - related party" } } }, "localname": "ProfessionalFeesRelatedParty", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "mdxl_PurchaseOfFurnitureAndEquipment": { "auth_ref": [], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Purchase of furniture and equipment" } } }, "localname": "PurchaseOfFurnitureAndEquipment", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "mdxl_R3AccountingLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents details pertaining to R3Accounting, LLC.", "label": "R3 Accounting LLC [Member]" } } }, "localname": "R3AccountingLLCMember", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetails", "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mdxl_SeriesAVotingPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Voting Preferred Stock [Member]" } } }, "localname": "SeriesAVotingPreferredStockMember", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "mdxl_SeriesBVotingPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series B Voting Preferred Stock [Member]" } } }, "localname": "SeriesBVotingPreferredStockMember", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "mdxl_TBGHoldingsCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tbg holdings corp member.", "label": "T B G Holdings Corp [Member]" } } }, "localname": "TBGHoldingsCorpMember", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "mdxl_TBGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "T B G [Member]" } } }, "localname": "TBGMember", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "mdxl_TurnkeyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Turnkey [Member]" } } }, "localname": "TurnkeyMember", "nsuri": "http://medixall.com/20210630", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetails", "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r21", "r60", "r213", "r214" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable and accrued expenses - related party", "negatedLabel": "Accounts payable and accrued expenses - related party" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r14", "r174", "r219" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r62", "r63", "r64", "r171", "r172", "r173", "r197" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Preferred stock (convertible)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r58", "r106", "r109", "r115", "r122", "r135", "r136", "r137", "r139", "r140", "r141", "r142", "r143", "r144", "r146", "r147", "r187", "r192", "r199", "r217", "r219", "r234", "r243" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r30", "r58", "r122", "r135", "r136", "r137", "r139", "r140", "r141", "r142", "r143", "r144", "r146", "r147", "r187", "r192", "r199", "r217", "r219" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedComputerSoftwareNet": { "auth_ref": [ "r259" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.", "label": "Capitalized Computer Software, Net", "verboseLabel": "Website and development costs" } } }, "localname": "CapitalizedComputerSoftwareNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r20", "r219", "r255", "r256" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r48", "r200" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of non-cash information" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r57", "r58", "r77", "r78", "r83", "r86", "r88", "r92", "r93", "r94", "r122", "r135", "r140", "r141", "r142", "r146", "r147", "r152", "r153", "r156", "r157", "r199", "r275" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "http://medixall.com/role/PreferredStockDetailsNarrative", "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommonStockDividendsShares": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.", "label": "Common stock issued in satisfaction of preferred stock dividend" } } }, "localname": "CommonStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r62", "r63", "r197" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical", "http://medixall.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r159" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13", "r219" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, $0.001 par value 750,000,000 shares authorized; 105,389,180 and 98,898,130 shares issued and outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r97", "r242" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Risks and Uncertainties" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r54", "r189" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r26", "r241" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r51", "r131" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r8", "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Cummulative unpaid dividends" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r166", "r240" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Less preferred stock dividends" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per common share - basic and diluted", "verboseLabel": "Basic and diluted LPS" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations", "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedEpsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and Diluted LPS Computation" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedEpsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r89", "r90" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r34", "r35", "r36", "r62", "r63", "r64", "r66", "r71", "r73", "r91", "r123", "r159", "r166", "r171", "r172", "r173", "r182", "r183", "r197", "r201", "r202", "r203", "r204", "r205", "r206", "r250", "r251", "r252", "r280" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical", "http://medixall.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r126", "r128" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Website and Development Costs" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r130", "r133" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Recoverability of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r38", "r106", "r108", "r111", "r114", "r116", "r233", "r236", "r238", "r248" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r59", "r72", "r73", "r105", "r177", "r184", "r185", "r249" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r33", "r175", "r176", "r178", "r179", "r180", "r181" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r50" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r50" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Accounts Payable, Related Parties", "verboseLabel": "Accounts payable and accrued expenses - related party" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilities": { "auth_ref": [ "r50" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities that result from activities that generate operating income.", "label": "Increase (Decrease) in Operating Liabilities", "verboseLabel": "Operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r50" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r50" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses- related party" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r127", "r129" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Website and development costs" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r51" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Common stock issued as compensation for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LaborAndRelatedExpense": { "auth_ref": [ "r40" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.", "label": "Personnel related expenses" } } }, "localname": "LaborAndRelatedExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r41" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Monthly fee" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/LegalContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Contingencies" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/LegalContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r23", "r58", "r110", "r122", "r135", "r136", "r137", "r140", "r141", "r142", "r143", "r144", "r146", "r147", "r188", "r192", "r193", "r199", "r217", "r218" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r58", "r122", "r199", "r219", "r235", "r245" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r25", "r58", "r122", "r135", "r136", "r137", "r140", "r141", "r142", "r143", "r144", "r146", "r147", "r188", "r192", "r193", "r199", "r217", "r218", "r219" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long Term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r26" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Note payable, net of current portion" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketingExpense": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.", "label": "Marketing and Consulting expenses" } } }, "localname": "MarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r48" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r48" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r48", "r49", "r52" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r31", "r32", "r36", "r39", "r52", "r58", "r65", "r67", "r68", "r69", "r70", "r72", "r73", "r84", "r106", "r108", "r111", "r114", "r116", "r122", "r135", "r136", "r137", "r140", "r141", "r142", "r143", "r144", "r146", "r147", "r198", "r199", "r237", "r247" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r67", "r68", "r69", "r70", "r74", "r75", "r85", "r88", "r106", "r108", "r111", "r114", "r116" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r76", "r79", "r80", "r81", "r82", "r85", "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Loss available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedEpsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Note payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses [Default Label]", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r208" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r207" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right-of-use-operating lease asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r51" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization of right-of-use operating lease asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r196" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization and Nature of Operation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/OrganizationAndNatureOfOperation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r29", "r219" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r4", "r6", "r125" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses- related party" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherSellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r42" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expense classified as other.", "label": "Other selling, general and administrative" } } }, "localname": "OtherSellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Offering costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireSoftware": { "auth_ref": [ "r43" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition from vendors of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments to Acquire Software", "negatedLabel": "Website development costs" } } }, "localname": "PaymentsToAcquireSoftware", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendRatePerDollarAmount": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "The amount per share used to calculated dividend payments on preferred stock.", "label": "Stock dividend" } } }, "localname": "PreferredStockDividendRatePerDollarAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Dividend rate" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r12", "r152" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Convertible Preferred stock, par value (in dollars per share)", "verboseLabel": "Convertible Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Convertible Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r12", "r152" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Convertible Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Convertible Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockTextBlock": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.", "label": "Preferred Stock" } } }, "localname": "PreferredStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/PreferredStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r12", "r219" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r6", "r124", "r125" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses - related party", "verboseLabel": "Prepaid expenses- related party" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r44" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from the sale of common stock, net of offering costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r44" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from the sale of preferred stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "PPP loan" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/LongTermDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r257", "r258" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r31", "r32", "r36", "r47", "r58", "r65", "r72", "r73", "r106", "r108", "r111", "r114", "r116", "r122", "r135", "r136", "r137", "r140", "r141", "r142", "r143", "r144", "r146", "r147", "r186", "r190", "r191", "r194", "r195", "r198", "r199", "r238" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net loss (unaudited)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r9", "r10", "r132", "r219", "r239", "r246" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Furniture and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r19", "r120" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Allowance for Uncollectible Accounts Receivable" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r168", "r211", "r212" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetails", "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": { "auth_ref": [ "r60", "r138", "r140", "r141", "r145", "r146", "r147", "r212" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.", "label": "Due from (to) related party" } } }, "localname": "RelatedPartyTransactionDueFromToRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r211" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetails", "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r168", "r211", "r214", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetails", "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r209", "r210", "r212", "r215", "r216" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r15", "r166", "r174", "r219", "r244", "r253", "r254" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r62", "r63", "r64", "r66", "r71", "r73", "r123", "r171", "r172", "r173", "r182", "r183", "r197", "r250", "r252" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r55", "r56" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r37", "r58", "r103", "r104", "r107", "r112", "r113", "r117", "r118", "r119", "r122", "r135", "r136", "r137", "r140", "r141", "r142", "r143", "r144", "r146", "r147", "r199", "r238" ], "calculation": { "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of prepaid expenses (accounts payable and accrued expenses) to related parties" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of potentially dilutive securities not included in the calculation of diluted net loss per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of computation of basic and diluted net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r213", "r214" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/RelatedPartyTransactionsDetails", "http://medixall.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r27", "r57", "r92", "r93", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r160", "r161", "r162", "r163", "r164", "r165", "r166" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "http://medixall.com/role/PreferredStockDetailsNarrative", "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "http://medixall.com/role/PreferredStockDetailsNarrative", "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r169", "r170" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangements" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance shares", "periodStartLabel": "Beginning balance shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r53", "r61" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r11", "r12", "r13", "r57", "r58", "r77", "r78", "r83", "r86", "r88", "r92", "r93", "r94", "r122", "r135", "r140", "r141", "r142", "r146", "r147", "r152", "r153", "r156", "r157", "r159", "r199", "r275" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "http://medixall.com/role/PreferredStockDetailsNarrative", "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r28", "r34", "r35", "r36", "r62", "r63", "r64", "r66", "r71", "r73", "r91", "r123", "r159", "r166", "r171", "r172", "r173", "r182", "r183", "r197", "r201", "r202", "r203", "r204", "r205", "r206", "r250", "r251", "r252", "r280" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical", "http://medixall.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical", "http://medixall.com/role/GoingConcernDetailsNarrative", "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r62", "r63", "r64", "r91", "r220" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/CondendsedConsolidatedBalanceSheetsParenthetical", "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical", "http://medixall.com/role/GoingConcernDetailsNarrative", "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Common stock issued for services (unaudited), Shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r12", "r13", "r159", "r166" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs (unaudited), Shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Proceeds received from sale of Preferred Stock,shares" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Common stock issued for services (unaudited)" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r12", "r13", "r159", "r166" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Proceeds from issue of stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Proceeds received pursuant to Private Placement Memorandum, net of $0 offering costs (unaudited)" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Value, Purchase of Assets", "verboseLabel": "Proceeds received from sale of Preferred Stock (unaudited)" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r16", "r17", "r58", "r121", "r122", "r199", "r219" ], "calculation": { "http://medixall.com/role/CondendsedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets", "http://medixall.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondendsedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reporting subsequent events.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r95", "r96", "r98", "r99", "r100", "r101", "r102" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted average number of common shares outstanding during the periods - basic and diluted", "verboseLabel": "Weighted average number of common shares outstanding" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://medixall.com/role/CondensedConsolidatedStatementsOfOperations", "http://medixall.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfBasicAndDilutedEpsDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r167": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r261": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r262": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r263": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r264": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r265": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r266": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r267": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r268": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r269": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r271": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r272": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r273": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r274": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r275": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r276": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r277": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r278": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r279": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r61": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" } }, "version": "2.1" } ZIP 44 0001553350-21-000868-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001553350-21-000868-xbrl.zip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end